Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2012

Role of Nicotinic Acetylcholine Receptors in Experimental Colitis
Shakir AlSharari
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medical Pharmacology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/2895

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Shakir D AlSharari 2012
All Rights Reserved

i

Role of Nicotinic Acetylcholine Receptors in Experimental Colitis
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
by
Shakir Dakheelallah Zayed AlSharari, PhD
Bachelor of Pharmaceutical Science
King Saud University, College of Pharmacy,
Kingdom of Saudi Arabia

Director: DR. M. IMAD DAMAJ
PROFESSOR, DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY
Virginia Commonwealth University
Richmond, Virginia
August, 2012

ii

ACKNOWLEDGMENTS
I would like to express my deepest gratitude to God, my family, my father and mother, bothers
and sisters and to my advisor, Prof. Imad M. Damaj, for his excellent guidance, caring, patience,
and providing me with an excellent atmosphere for doing research and supporting my research,
most importantly, his friendship during my graduate studies at Virginia Commonwealth
University. He encouraged me to not only grow as a pharmacologist but also as an instructor and
an independent thinker. Patiently corrected consistent notation in my writing, reading and
commenting on countless revisions of this manuscript. I have been amazingly fortunate to have
an advisor who gave me the freedom to explore on my own and at the same time the guidance to
recover when my steps faltered. He taught me how to question thoughts and express ideas. His
patience and support helped me overcome many crisis situations and finish this dissertation. I
hope that one day I would become as good an advisor to my students as Prof. Damaj has been to
me. Also, I would never have been able to finish my dissertation without the guidance of my
committee members, help from friends, and support from my family. Thanks to the members of
my graduate committee:
Prof. Hamid I Akbarali, for the many valuable discussions that helped me understand my
research area better and for his thought-provoking questions that helped build my critical
thinking, and for his expertise in GI research, for guiding my research for the past several years
and helping me to develop my background in physiology.

iii

Prof. Guy A Cabral, for his suggestions who let me experience the research in his lab with his
amazing lab members and taught me the practical issues beyond the textbooks. I am indebted to
him for his continuous encouragement and guidance.
Prof. Srinivasa M Karnam, for taking time to meet and discuss with me any questions or
concerns I had about my research; and he was always willing to help and give his best
suggestions.
Prof. Kimber White, for I am deeply grateful to him for the long discussions that helped me sort
out the technical details of my work and allowing me to work in his lab.
Special thanks goes to Prof. Aron Lichtman, who I cannot thank enough for his suggestions over
all these years and for providing his time to participate in my final defense committee at the last
moment and for his statistical expertise.
Million thanks for my committee members for their insightful comments and constructive
criticisms at different stages of my research were thought-provoking and they helped me focus
my ideas. I am grateful to them for holding me to a high research standard and enforcing strict
validations for each research result, and thus teaching me how to do research. I would like to
express my sincere thanks to all the members, past and present, of the Damaj lab. Each of you in
some way contributed to my growth as a scientist and helped keep me sane! I will never forget
how wonderful you all are. My research would not have been possible without their helps. I am
also indebted to the members of the pharmacology and toxicology dept. with whom I have
interacted during the course of my graduate studies. A very special thank you to my friends for
the support they’ve lent me over all these years. Thanks a lot for everything. I owe my gratitude
for God and to my family and all those people who have made this dissertation possible and

iv

because of whom my graduate experience has been one that I will cherish forever. Many friends
have helped me stay sane through these difficult years. Their support and care helped me
overcome setbacks and stay focused on my graduate study. I greatly value their friendship and I
deeply appreciate their belief in me. I am also grateful to the Sheffield’s family that helped me
adjust to a new country.
My very special thanks to my parents, sisters, and brothers whom this dissertation is dedicated
to and I owe everything I am today, for their unwavering faith and confidence in my abilities and
allowing me to be as ambitious as I wanted. It was under God and their watchful eye that I
gained so much drive and an ability to tackle challenges head on. My family has been a constant
source of love, concern, support and strength all these years.
Finally, I appreciate the financial support from Ministry of Higher Education (MOHE) in
Kingdom of Saudi Arabia. Last, words cannot express how grateful and blessed I feel having
such wonderful and supportive people in my life especially from Prof. Damaj. I’m glad I make
you proud.

v

Table of Contents

Page

Acknowledgements .............................................................................................................iii
List of Abbreviations...........................................................................................................xi
List of Figures.................................................................................................................... xii
List of Tables......................................................................................................................xiv
Abstract .............................................................................................................................xv
Chapter 1. GENERAL INTRODUCTION and REVIEW OF THE LITERATURE
1.1.

Ulcerative Colitis: Definition, Clinical presentation, and Diagnosis………………......1

1.2.

Abnormalities in Immune Responses in Ulcerative Colitis …………….......................2

1.3.

Conventional Pharmacological Therapy……………………………………………….3

1.4.

Smoking Cigarette and Ulcerative Colitis disease……………………………………..4

1.5.

The Effectiveness of Nicotine Replacement Therapy in Ulcerative Colitis patients.….5

1.6.

The Effectiveness of Nicotine treatment in Experimental Animal Colitis Model……..6

1.7.

The Concept of “Cholinergic Anti-inflammatory Pathway” and involvement of α7
nicotinic Receptor…………………………………………………..……………………...7

1.8.

Nicotinic Receptors: Composition, Distribution, and Subtypes ………………………9

1.9.

Animal Experimental Models of Colitis…………………………………………….....11

vi

1.10.

Using Genetically Modified Animals: a complementary approach to study the role of

nAChR subtypes in murine colitis model …………………………………………………..12
1.11.

Dissertation Objectives………………………………………………………………….14

Chapter 2. Materials and Methods
2.1. Animals…………………………………………………………………………….15
2.2. Drugs……………………………………………………………………………….15
2.3. Dextran Sulphate Sodium (DSS)-induced Colitis Model………………………….16
2.4. Assessment of the Severity of Colitis: Disease Activity Index……………………17
2.5. Colonic Histology Assessment…………………………………………………….17
2.6. Assessment of Colonic Myeloperoxidase (MPO) Activity………………………..18
2.7. Tumor Necrosis Factor-alpha (TNF-α) Levels…………………………………….19
2.8. Total Protein Quantification ………………..……………………………………..19
2.9. Nicotine and Cotinine Plasma Levels………………….………………………….19
2.10. Nicotine and metabolites HPLC/MS/MS analysis……………………………….20
2.11. Statistical Analysis……………………………………………………………….21
Chapter 3. Results: THE IMPACT OF NICOTINE ROUTE OF ADMINISTRTION IN
MURINE DSS-INDUCED COLITIS
3.1. Introduction………………………………………………………………………………..23

vii

3.2. Materials and Methods:
3.3. Chronic nicotine treatment………………………………………………………………...26
3.3.1. Study 1. Dextran sulfate sodium (DSS) dose response curve……………………..…….26
3.3.2. Study 2. Effect of Oral (-)-nicotine administrations…………………………………….26
3.3.3. Study 3. Effect s.c. (-)-nicotine administrations………………………………………….26
3.3.4. Study 4. Effect (-)-nicotine administration through mini pump………………………….26
3.3.5. Study 5. Effect of Oral Cotinine Administration…………………….……….…………..27
3.4. Results
3.4.1. Characterization DSS dose-response curve on colitis severity in the mouse………..…..27
3.4.2. Oral Nicotine Administration Attenuates DSS-induced Colitis………………………...29
3.4.3. Effect of subcutaneous and mini pump nicotine treatments on DSS-induced colitis…...30
3.4.4. Effect of cotinine, the main metabolite of nicotine, in the DSS-induced colitis model...31
Chapter 4. THE ROLE OF α7 NICOTINIC RECEPTORS IN MOUSE DSS COLITIS
MODEL
4.1. Introduction .………………………………………………………………...……………47
4.2. Material and Methods
4.2.1. Study 1: DSS-induced colitis model in α7 KO and WT nAChR mice…………………49

viii

4.2.2. Study 2: Effect of chronic PHA-543613 and choline treatment in DSS-induced colitis
model……………….……………………………………………………………………...…….49
4.2.3. Study 3: Effect of chronic PNU-120596 treatment in DSS-induced colitis model……….49
4.3. Results
4.3.1. DSS-induced colitis in α7 KO mice………………………………………………….……49
4.3.2. Effect of α7 nAChR agonists and PAM in DSS colitis model ……………………….......50
4.3.2.1. Effect of PHA-543613 on DSS-induced colitis model in mice……………..…………..50
4.3.2.2. Effect of Choline on DSS-induced colitis model in mice…………….……..…………..52
4.3.2.3. Effect of α7 nAChR positive allosteric modulator (PAM) in DSS colitis model….........52
Chapter 5. THE ROLE OF NON-α7 NICOTINIC RECEPTORS IN EXPERIMENTAL
COLITIS
5.1. Overview………..……………………………………………..…………………………….62
5.2. Materials and Methods
5.2.1. Study. Role of non-α7 nicotinic receptor (α5, β2, and α9) subtypes in DSS-induced colitis
model in mice…………………………………………………………………………………….64
5.3. Results……………………………………………………………………………………….64
Chapter 6. General discussion, summary and future Studies
6.1. DSS-induced colitis model dose-response curve in mice……………..……………70

ix

6.2. Influence of nicotinic dose and route of administration in mouse DSS colitis
model……………………………………………………………………………….…..71
6.3. Influence of α7 nicotinic receptors in mouse DSS colitis model……….…………75
6.4. Involvment of non-α7 nicotinic receptors in mouse DSS colitis model….….……79
6.5. Summary ……………………….............................................................................81
6.6. Future Directions.....................................................................................................83
References………………………………………………………………………………….….85

x

LIST OF ABBREVIATIONS

CC

Choline chloride

IL

interleukin

α-RgIA α-conotoxin RgIA
TNF-α

Tumor necrosis factor-alpha

DAI

disease activity index

AUC

area under the curve

IBD

inflammatory bowel disease

UC

Ulcerative Colitis

CD

Crohn’s disease

IFN-γ

interferon γ

LPS

lipopolysaccharide

STAT3 signal transducer and activator of transcription 3
TFG-β

transforming growth factor β

TNBS

trinitrobenzene sulphonic acid

ACh

acetylcholine

i.p.

intraperitoneal

KO

knockout

WT

wild-type

MLA

methyllycaconitine

MP

mini pump

nAChR nicotinic acetylcholine receptor
NIC

nicotine

SEM

standard error of the mean

s.c.

subcutaneous

DSS

dextran sodium sulfate

xi

List of Figures

Figure 1.

Colonic inflammation was aggravated after DSS exposure to mice in a doserelated manner ………………………………..……………………….……32

Figure 2. Aggravation of inflammatory markers after 7 days of exposure to different
doses of DSS in mice...................................................................................33

Figure 3.

Histological scores from colons after 7 days of exposure to water or different
doses of DSS …………………………….……………………….………..34

Figure 4.

Histological analysis of representative colons from mice after 7 days of
exposure to water or different doses of DSS ……………………………...35

Figure 5. Survival rate of C57Bl/6 mice treated with DSS (2.5 & 5%) for 7 days then 7
days without DSS (recovery phase) ……………………………………….36

Figure 6.

Oral nicotine treatment suppressed the severity of DSS-induced colitis in
mice………………………………………………………………………..37

Figure 7.

Oral nicotine treatment affects colonic TNF-α levels, histological damage
score and appearance in DSS-induced colitis……………………………..38

Figure 8. Effect of chronic s.c. nicotine administration on the severity of DSS-induced
colitis in mice……………………………………………………………..39

Figure 9. Influence of nicotine infusion via mini pump in DSS-treated mice on DAI,
histological damage and colon length……………………………………40

Figure 10. Lack of suppression of the severity of colitis by oral cotinine……………41

xii

Figure 11.

Colonic inflammation was aggravated after DSS exposure in α7-deficient
mice………………………………………………………………………….54

Figure 12.

Histopathologic changes in colonic tissues and colonic TNF α level following
1 week of dextran sulphate sodium administration in α7 deficient mice…...55

Figure 13.

Effect of PHA-543613 on DAI and inflammatory markers in C57Bl/6 mice
with DSS colitis.…………………………………………………......……..56

Figure 14.

Histological analysis of representative colons from C57Bl/6 mice after 7 days
of exposure to water, vehicle, or PHA-543613 treatment ………….……..57

Figure 15.

Chronic oral choline treatment suppressed the severity of DSS-induced colitis
in mice ………………………………………………………………..……58

Figure 16.

Histological analysis of representative colons from C57Bl/6 mice after 7 days
of exposure to water, vehicle, or choline treatment in C57Bl/6 mice with DSS
colitis………………………………………………………………....………59

Figure 17.

Effect of PNU-120596 on DAI, colonic TNF-α level and colon length in
C57Bl/6 mice with DSS colitis……………………………………..….……60

Figure 18. Influence of PNU-120596 on histological damage score in DSS-treated mice..61
Figure 19.

Clinical evaluation of non-α7 nicotinic receptor subtypes, particularly α5 and
β2 in DSS-induce colitis model in mice………………………………….….66

Figure 20.

Effect of repeated subcutaneous α-RgIA administration on the severity of
DSS-treated C57BL/6J mice………………………………………………...68

Figure 21.

Effect of repeated subcutaneous α-RgIA treatment in DSS-treated C57BL/6J
mice on histological damage, and inflammatory marker…………………....69

xiii

List of Tables

Table 1: Daily fluid volume consumption……………………………..…………………… 42
Table 2: Effect of s.c. nicotine treatment on colonic TNF-α levels in DSS-treated mice…...43
Table 3: Effect of chronic nicotine infusion on colonic TNF-α levels in DSS-treated mice..44
Table 4: Summary of plasma levels of nicotine and its metabolite cotinine after chronic
nicotine treatment using s.c. injection, infusion (mini pumps) or oral routes of
administration……………………………………………………………………45

Table 5: Summary of plasma levels of cotinine after chronic oral cotinine treatment……..46

xiv

Abstract
Role of Nicotinic Acetylcholine Receptors in Experimental Colitis
By Shakir Dakheelallah Zayed AlSharari, B.S.Pharm
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University, 2012
Major Director: Dr. M. Imad Damaj
Professor, Pharmacology and Toxicology

Substantial evidence in the literature shows that tobacco smoking has complex and divergent
effects on inflammatory bowel diseases (IBD). It ameliorates ulcerative colitis (UC); whereas it
aggravates the risk of Crohn’s disease (CD) and affects the disease course and severity. Studies
have shown that nicotine has a positive influence on symptoms of UC. Also, it is demonstrated
that nicotinic acetylcholine receptor, especially α7 subunit plays an essential component in the
vagus nerve-based cholinergic anti-inflammatory effects. In the present study, we explored the
effect of nicotine and α7 nicotinic agonists treatment in the DSS colitis mouse model. We also
investigated the effects of cotinine, a major metabolite of nicotine, in the model. Methods:
Different groups of C57BL6 mice, as well as α7, α5, and β2 nicotinic receptor knock out mice,
and their littermates wild-type nicotinic receptor male adult mice were given DSS solution freely
in the drinking water for 7 consecutive days after which tap water was given on the 8th day. We
measured a Disease Activity Index (DAI) that includes body weight loss, blood presence in
stools, stool consistency, local rectal irritation and length of the colon. The mice were then
sacrificed on day 8 to allow examination of the entire colon. Disease severity and colon tissue
histology and inflammatory markers including colonic myeloperoxidase (MPO) and colonic
tumor necrosis factor-α (TNF-α) were evaluated. Levels of MPO and TNF-α were determined by
enzyme-linked immunosorbent assay analysis of the homogenized colon samples. The effect of
oral, subcutaneous, mini pump nicotine, and oral cotinine treatments were examined on

xv

experimental colitis induced by 2.5% DSS in mice. In addition, we measured the plasma levels
of the nicotine and cotinine in our treatment protocols. Results: The DSS 2.5% model of colitis
is easily induced in mice. Administration of low doses of oral nicotine (12.5 and 25 µg/ml), but
not high doses in DSS-treated mice displayed a significant decrease in disease activity index
value, total histological damage scores, as well as colonic level of TNF-α compared to the
control group. However, the anti-inflammatory effect of nicotine was not seen with chronic s.c.,
mini pump nicotine or oral cotinine administration. Differences in plasma levels of nicotine and
cotinine do not seem to account for this lack of effect. Moreover, neither nicotine nor cotinine
reversed colon length shortening in DSS-treated mice, except with the 0.5 mg/kg s.c. dose of
nicotine. There was no change in MPO activity among the groups treated with oral or s.c.
nicotine. Cotinine oral administration on its own failed to show a significant effect in the DSS
model of colitis. α7 KO mice displayed a significantly increased in DAI value starting from day
4 till day 8, histological damage scores and TNF-α levels of were increased significantly
compared to their littermate WT mice. Moreover, pretreatments with PHA-543613 (8 mg/kg), a
selective α7 agonist, and choline chloride (40 ug/ml), an α7 nAChR natural agonist, significantly
reduced clinical parameters in DSS-treated mice; however, they slightly inhibited the increase in
the colonic TNF-α levels compare with vehicle DSS-treated mice. Moreover, PNU-120596 (3
mg/kg), a positive allosteric modulator for α7 nAChRs, significantly reduced DAI value and total
histological damage score in DSS-treated mice. Conclusion: Results obtained from this study
highlight that dose and route of administration play a critical role in the protective effect of
nicotine in the DSS mouse colitis model. Also, these data suggest that α7 nAChR has a
protective role in colitis with narrower therapeutic index. Data obtained from this study further

xvi

understanding of the effect of nicotine in UC and may contribute in the development of new
pharmaceutical designs for targeting nAChRs for the treatment of ulcerative colitis.

xvii
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CHAPTER ONE
General Introduction
1.1.

Ulcerative Colitis: definition, clinical presentation, and diagnosis

Ulcerative colitis (UC) is one of the main two entities of inflammatory bowel diseases (IBD),
beside Crohn’s disease (CD). Differences between these two typical IBD disorders are related to
the disease nature and location as a result of abnormal immune response, various genetic and
environmental factors (Baumgart and Carding, 2007; Strober et al., 2007). Interestingly, cigarette
smoking has a dual opposite influence on these two diseases; it exacerbates CD, but ameliorates
the course of UC disease (Tobin et al., 1987). For that reason, in my dissertation, I pay special
attention to UC. I also discuss the influence of nicotine and the involvement of nicotinic receptor
subtypes in UC. Ulcerative colitis is a chronic inflammatory disease with recurrent symptoms
and significant morbidity of unknown etiology, due partly to genetic susceptibility to
environmental factors that misdirect the mucosal immune system response to attack the epithelial
layer of the colon causing inflammation and was first described by Sir Wilks (Wilks S, 1859).
UC is characterized by inflammation of the mucosa and occasionally the submucosa of the colon
and it is the most common form of inflammatory bowel disease worldwide that results in
excessive mononuclear cell and neutrophil infiltration into mucosa and submucosa vicinities that
affects primarily the distal colon and rectum (Hanauer, 1996). The incidence of UC in North
America ranges from 2.2 to 14.3 cases per 100,000 (Loftus, 2004) and the adult prevalence of
UC in the United States has ranged between 37 and 238 per 100,000 (Loftus, 2004; Kappelman
et al., 2007) with age range between 15 and 30 years. Northern Europe and North America
populations have the highest incidence and prevalence of IBD (Ahuja and Tandon, 2010).
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1.2.

Abnormalities in Immune Responses in Ulcerative Colitis

UC is associated with alterations of innate or adaptive arms of the immune response. The
increased levels of IgM, IgA, and IgG are common in IBD, with an increase in IgG1 antibodies
in UC (Takahashi and Das, 1985). In addition, cytokines are up-regulated at the mucosa of
patients with UC, and play central components of the inflammatory pathways in ulcerative colitis.
Abnormalities of adaptive immunity in the UC are defined by mucosal CD4+ lymphocytes, the T
helper 1 (Th1) and T helper type 2 cells (Th2) paradigm. Immune responses have been classified
based on the prominent cytokine profile in different disease conditions. Although this traditional
concept of mucosal immunology considered ulcerative colitis mainly as a Th2-mediated
response, due to the lack of IFN γ expression increase rather than IL-4 elevation (Fuss et al.,
1996), recent research focuses on the alternative Th2 responses such as role of IL-13 in UC. This
approach indicates that there is a significant increase of IL-13 (Fuss et al., 2004, Heller et al.,
2005). It has been reported that both of IL-13 receptors, IL-4Rα and IL-13Rα2, were expressed
in intestinal epithelial cells and that IL-13 has an important role on epithelial barrier function
(Heller et al., 2005) which indicates the involvement of IL-13 in UC signaling pathogenesis
(Fuss and Strober, 2008). It has been proposed that colonocytes are the main players in the UC
pathogenesis since the inflammation in UC does not reach into the small intestine (for review see,
Danese and Fiocchi, 2011). The defects in UC epithelial include impaired epithelial barrier and
reduced peroxisome proliferator activated receptor γ (PPAR-γ) expression (Dubuquoy et al.,
2003). In fact, PPARγ ligands treatment has been reported to reduce colonic inflammation in
animal colitis models (Su et al., 1999; Dubuquoy et al., 2006) and reduce the pro-inflammatory
cytokine including IL-1β and TNF-α (Dubuquoy et al., 2006).
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Clinical Presentations. The diagnosis of colitis is generally established by assessment of
inflammatory markers followed by colonoscopy, with biopsy of pathological lesions to
determine specific histologic characteristics. The hallmark symptoms of UC are intermittent
bloody diarrhea, rectal urgency, and tenesmus (straining at stool) (Kornbluth and Sachar, 2004).
The ultimate diagnosis relies on a combination of history, endoscopic finding, histologic features.
Patients typically present with bloody diarrhea and passage of pus and/or mucus that often
persists for months and is accompanied by abdominal cramping during bowel movements. In
mild ulcerative colitis, rectal mucosal inflammation (proctitis) is sometimes associated with fecal
urgency and the presence of blood. In moderate disease, small erosions are present, however, in
severe UC, ulcerations with bleeding are seen.
Histological Features. UC is not a static disease but is a disease that frequently changes as a
result of active stage and remissions. In UC, inflammation is characteristically limited to the
mucosal layer, with inflammatory cell infiltrates into lamina propria. Infiltrates consist primarily
of lymphocytes, plasma cells, and granulocytes; neutrophils can invade crypt epithelium causing
cryptitis and accumulate resulting in crypt abscesses (Loddenkemper, 2009). Other histological
features include depletion of goblet cells, alteration of shapes and sizes of crypts, and colonic
ulcerations.
1.3.

Conventional Pharmacological Therapy

Management of ulcerative colitis involves acute treatment of all inflammatory symptoms,
followed by maintenance of remission. Treatment of UC, generally depends on the disease
severity (mild, moderate, or severe) (Stange et al., 2008; Travis et al., 2008; Kornbluth and
Sachar, 2010), and most commonly requires sulfasalazine and 5-aminosalicylates given orally or
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rectally (either suppository or enema), representing first-line therapy for UC, with approximate
50% remission rate (Nielsen and Munck, 2007). Many UC patients receive sub doses of drugs
(mainly the aminosalicylates), continue to take glucocorticoids as a maintenance therapy, or may
require biologic agents, such as immunosuppressive therapy, azathioprine, 6-mercaptopurine, or
cyclosporine to control the symptoms. However, 5-aminosalicylic acid drugs and glucocorticoids
have poor efficacy and frequency of adverse effects such as nausea, vomiting, fever, headache,
and gastrointestinal distress for 5-ASA with the frequency rate of these adverse events between
20-30% and a 5-10% withdrawal rate (Moss and Peppercorn, 2007) and for steroids these side
effects include weight gain, fluid retention, immune suppression, hypokalemia, hypertension
(Ardizzone and Bianchi Porro, 2002) that limit their use (Rosenberg and Peppercorn, 2010). It is,
therefore, highly desirable to develop more efficacious treatments that elicit fewer side events
than presently used medications. Alternative medicine treatments include probiotics, nicotine
patches and fish oil. In some severe cases, colectomy is a final option.
1.4.

Cigarette Smoking and Ulcerative Colitis disease
UC has been linked to tobacco smoking for more than three decades. Smoking cigarettes is

associated with less frequent exacerbations of ulcerative colitis (Cosnes, 2004). Moreover,
tobacco smoking has been reported to often have a beneficial outcome on the course of activity
of UC in smokers (Boyko et al., 1988; Mokbel et al., 1998; Gheorghe et al, 2004; Höie et al.,
2007) and associated with fewer hospitalizations rate, decrease the clinical disease activity, and
need for therapy (Birrenbach and Bocker, 2004) and to decrease the need for colon surgery
(Odes et al., 2001; Cosnes, 2004). For example, smokers with UC who quit smoking experienced
an increase in disease activity; however, mild disease activity and symptom improvements were
seen in ex-smokers who returned to smoking (de Castella 1982; Motley et al., 1987; Ruda et al.,
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1989; Kuisma et al., 2004). The etiopathology of UC and underlying mechanism of smoking in
UC is still unclear. Smoking and nicotine have multiple actions which can affect gut
inflammation. It has been demonstrated that cigarette smoking decreased intestinal permeability
in healthy volunteers (Prytz et al., 1989; Suenaert et al., 2000); however, UC disease in smokers
did not demonstrate intestinal permeability decrease when compared with the nonsmokers
(Benoni and Prytz, 1998) which is most likely to occur in UC patients, since smoking cigarette is
protective in UC.
1.5.

The Effectiveness of Nicotine Replacement Therapy in Ulcerative Colitis patients
Although cigarette smoke contains hundreds of substances, there is evidence that nicotine
and its metabolites account for the beneficial effect of smoking. However, since nicotine is
metabolized to cotinine (> 80%) and other metabolites (Benowitz, 1998; Gorrod and Jacob,
1999), it is possible that these latter metabolites account, at least in part, for the protective
effect of smoking in UC. Nicotine has shown UC symptoms improvement in some clinical
trials with different formulations including gum (43% of 7 patients, Lashner et al., 1990),
transdermal patches (78% of 18 patients, Srivastava et al., 1991; 70% of 10 patients,
Guslandi and Tittobello, 1996), and enema (71 and 73% of 7 and 22 patients, respectively;
Sandborn et al., 1997; Green et al., 1997 respectively), although it has some few adverse
effects which included nausea, headache and sleep disturbance (Pullan et al., 1994;
McGilligan et al., 2007). Since most of the previous clinical studies showing nicotine
replacement therapy in humans, including nicotine gum, transdermal and enemas, decreases
the UC disease activity, but with inconsistent and conflicting results due to the different
nicotine formulas, various doses of nicotine, duration of the studies, type of the studies, and
number of subjects in these studies, and their interpretation has been confounded by the side
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effects experienced by individuals as a result of the high systemic nicotine concentrations
required (Pullan et al., 1994; Cosnes et al., 2004; McGilligan et al., 2007). In addition,
nicotine in different formulations including gum, patches, and enema, was not effective in
treating disease relapses and remission (Perera et al., 1984; Thomas et al., 1996; Ingram et al.,
2005). Furthermore, clinical studies conducted by Green et al., (1997) and Sandborn et al.
(1997) tested nicotine enemas, in which nicotine is applied directly to the colon, indicated
that UC symptoms, endoscopic features, and histologically-revealed damage were improved
with only a few of the patients reporting some side effects. These initial studies indicate that
nicotine applied directly to the colon, perhaps in an enema formulation, may be beneficial
while causing fewer side effects.
1.6.

The Effectiveness of Nicotine treatment in Experimental Animal Colitis Model

Similar findings with nicotine have been reported in rodent models of colitis. For example, low
doses of oral nicotine treatment (12.5 µg/ml) improved the macroscopic and inflammatory
damage of experimental colitis in rats, but not with the high doses (250 µg/ml) (Eliakim et
al.,1998, 2001). A similar observation has been reported by Qiu et al., (1997), in which they
showed that low doses of oral nicotine (5-20 µg/ml) reduced colonic damage and MPO activity;
whereas, at dose of 50 µg/ml increased ulceration area and MPO activity in rats. Ghia et al.,
(2006) reported also that 20 µg/ml of nicotine in drinking water decreased clinical signs of
inflammation and reduced colonic myeloperoxidase (MPO) activity and TNF-α levels in the
mouse DSS model.

However, chronic intraperitoneal injection of nicotine (0.25 and 2.50

µmol/kg) in DSS-induced colitis in mice failed to decrease clinical signs of inflammation,
colonic TNF levels and histological features of the disease (Snoek et al., 2010). Although
experimental studies indicate that the beneficial effects of nicotine in UC is due to its anti-
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inflammatory effect by decreased pro-inflammatory cytokines production in healthy subjects and
active UC patients (Madretsma et al., 1996; Bhatti and Hodgson, 1997; Louvet et al., 1999;
Eliakim and Karmeli, 2000; Sykes et al., 2000), nicotine alters adherent mucus thickness in
rabbits colonic mucosa; reduced by low doses and increased by high doses of nicotine in control
animals (Zijlstra et al., 1994). In experimental animal models of colitis, nicotine also has been
shown to be effective in the treatment of intestinal inflammation (Sykes et al., 2000; Eliakim and
Karmeli, 2003). Overall, both clinical and animal studies with nicotine treatment suggest the
usefulness of nicotine in UC disease activity.
1.7.

The Concept of “Cholinergic Anti-inflammatory Pathway” and involvement of α7
nicotinic Receptor
Many studies reported that the central nervous system (CNS) can regulate the innate immune

responses through the peripheral nervous system (PNS) (Gallowitsch-Puerta and Tracey, 2005;
Czura and Tracey, 2005; Pavlov and Tracey, 2006; Gallowitsch-Puerta and Pavlov, 2007). Since
cholinergic fibers innerve many lymphoid organs, for example, the immune organ thymus,
express α7 (Navaneetham et al., 1997), also α3 and α5 nicotinic receptors subunits (Mihovilovic
and Roses, 1991 and 1993) which are expressed by thymocytes. Nicotinic receptors may mediate
the immune-modulatory effect of nicotine (Conti-Fine et al., 2000), the presence of nAChRs on
immune cells might play a role in the interaction between the nervous and immune systems
(Battaglioli et al., 1998; Kawashima and Fujii 2000; 2003; Fujii, 2004).
The anti-inflammatory effect of nicotine is also supported by the finding that nicotinic
receptors can regulate inflammation locally and systemically primarily through the vagus nerve
so-called “cholinergic (nicotinic) anti-inflammatory pathway” which is a link between
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parasympathetic and innate immune system and is one of the main endogenous regulatory
mechanism to control the innate immune responses and ameliorates systemic inflammation by
regulating the production of pro-inflammatory cytokines mainly through activation of α7
nAChRs on macrophages surface (Borovikova et al., 2000; Tracey et al., 2001, 2002; Wang H et
al., 2003, 2004; Ulloa, 2005; de Jonge and Ulloa, 2007). It is reported that nicotinic acetylcholine
receptor, especially α7 subunit plays an essential role in the cholinergic anti-inflammatory effects
(Kelso et al., 2006; Hamano et al., 2006). Other studies reported that vagus nerve activation
attenuates intestinal inflammation via α7 nAChRs in animal model of postoperative ileus (de
Jonge et al., 2005) and in experimental colitis (Ghia et al., 2006; 2007). Moreover, α7 nAChR
agonists has shown anti-inflammatory effects in various animal models of inflammation (Damaj
et al., 2000; Giebelen et al., 2007), peritoneal macrophages and in human whole blood (Li J et al.,
2011), in a murine endotoxemia and severe sepsis model (Pavlov et al., 2007), and decreased
severity of experimental pancreatitis (van Westerloo et al., 2005). These anti-inflammatory
effects appear to be mediated by the activation of α7 nAChRs on immune cells such as
macrophages in human (Wang et al., 2003; 2004) and mice (Wang et al., 2003; 2004;
Kawashima et al., 2007).
Nicotine is a full agonist at α7 nAChRs (Gerzanich et al., 1995; and Feuerbach et al., 2005).
α7 nAChRs form homo-pentameric subtypes in the CNS and peripheral nervous system
(Couturier et al., 1990; Keyser et al., 1993; Sharples and Wonnacott, 2001). α7 subtype is a wellcharacterized nAChR subunit (Sharma et al., 2008) and exhibits distinct physiological and
pharmacological profiles relative to other nAChR subtypes. It is characterized by its high
calcium permeability (Shen and Yakel, 2009), the rapid desensitization after agonist activation,
and the blockade by methyllycaconitine and α-bungarotoxin (for reviews, Dajas-Bailador and
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Wonnacott, 2004; Hogg and Bertrand, 2004). Previous studies demonstrated that α7 nAChR
subunits express on macrophages can inhibit transcriptional activity of NF-κB, hence decrease
the release of pro-inflammatory cytokines (Nizri et al., 2006; Yoshikawa et al., 2006; Parrish et
al., 2008). During inflammation, activation of α7 nAChRs is associated with calcium influx and
inhibits activation of nuclear factor κB (NF κB) (Borovikova et al., 2000; Tracey et al., 2005;
2009). From our previous study (Abdrakhmanova et. al., 2010), we showed that in vitro nicotine
suppressed firing of action potential in colonic sensory neurons from DSS-treated mice.
Moreover, we showed that nicotine fails to suppress multiple-spike action potential firing in
inflamed mouse neurons in the presence of the α7 competitive antagonist MLA, which was
confirmed by using natural α7 agonist choline chloride which suppressed hyper excitability of
inflamed colonic sensory neurons which support the essential role of α7 nAChRs in the
mechanism of nicotine-induced suppression of action potential firing in inflamed colonic
neurons. Since α7 nicotinic receptors involve in the cholinergic anti-inflammatory pathway
(Wang et al., 2003; de Jonge et al., 2005; Ulloa, 2005) and earlier studies reveal the important
role of α7 nAChRs in controlling gut inflammation, using selective α7 agonists and a positive
allosteric modulator for α7 nAChRs could open a new therapeutic avenue and represent a
promising pharmacological strategy for the treatment of inflammation in ulcerative colitis.
1.8.

Nicotinic Receptors: Composition, Distribution, and Subtypes
Neuronal nicotine acetylcholine receptors (nAChRs) are pentameric ligand-gated ion

channels that exist as homomeric or heteromeric complexes of α and β subunits. To date, 12
neuronal subunits (α2-α10 and β2-β4) have been identified in mammals (see Gotti et al., 2007 for
review). Nicotine exerts its effects by activating nicotine acetylcholine receptors. Nicotinic
receptors are found in nerves of the central and peripheral nervous systems and in the autonomic
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ganglia, colonic submucosal and myeteric plexuses. They are also present in non-neuronal cells
including human immune cells. Human lymphocytes express mRNA for nAChR subunits for α3,
α4 (Hiemke et al., 1996), α3, α5, and β4 (Mihovilovic et al., 1998; Mihovilovic and Roses, 1991,
1993). Human mononuclear leukocytes expressed mRNAs encoding the α2, α5, and α7 subunits
(Sato et al., 1999). They are expressed in the enteric nervous system, in enteric plexuses
(Kirchgessner and Lu, 1998; Obaid et al., 2005). For example, many nAChR subunits mRNA for
α3, α5, α7, β2, and β4 have been detected in the intestine (Kirchgessner and Lu, 1998; Obaid et
al., 1999a,b; Obaid and Lindstrom, 2000). Nicotinic receptors have been identified in colonic
epithelial HT29 cells, including α3, α5, α7 nAChR subunits (Summers et al., 2003). α7 nAChRs
form homo-pentameric subtypes in the central nervous system (CNS) and peripheral nervous
system (PNS) (Couturier et al., 1990; Keyser et al., 1993; Sharples and Wonnacott, 2001).
Although these receptors are predominantly expressed in neuronal tissues, several types of
immune cells express α7 nAChR mRNA, including macrophages (Tracey, 2002; Kawashima et
al., 2007 and Rosas-Ballina et al., 2008), T-cells (Fujii et al., 1999), B-cells (Fujii et al., 1999;
Sato et al., 1999), microglia (Shytle et al., 2004), monocytes (Matsunaga et al., 2001;
Kawashima et al., 2007) and dendritic cells (Aicher et al., 2003; and Kawashima et al., 2007) and
express on endothelial cells (Wang Y et al., 2001; Abbruscato et al., 2002; Moccia et al., 2004;
Saeed et al., 2005; Kawashima et al., 2007). α9 subunit can form functional homopentamer
nicotinic receptors (Elgoyhen et al., 1994) and functional heteromeric with α10 subunits
(Elgoyhen et al., 2001; Sgard et al., 2002). α9 and α10 subunits have restricted anatomical
tissue expression (Nashmi and Lester, 2006; Gotti et al., 2006). They have not been detected in
the brain and spinal cord (Elgoyhen et al., 2001; Sgard F et al., 2002). Gene transcripts for α9 or
α10 have been reported within hair cells of the inner ear (Elgoyhen et al., 1994; Elgoyhen et al.,
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2001; and Vetter et al., 2007), skin keratinocytes (Arredondo J et al., 2002), in the sperm (Kumar
and Meizel, 2005), dorsal root ganglion (DRG) neurons (Lips et al., 2002), the pars tuberalis of
the pituitary (Sgard et al., 2002), and lymphocytes (Peng H et al., 2004). α10 is expressed in
arteries (Bruggmann et al., 2002; 2003) and sympathetic ganglia (Lips et al., 2006). The
functional significance of α9 and α10 in these tissues is not known. Finally, both α9 and α10 are
present in many immune cells (Lustig et al., 2001, Peng et al., 2004; Galvis et al., 2006;
Kawashim et al., 2007; Wessler and Kirkpatrick, 2008). The α9 and α10 nAChR subunits have
been detected in human cultured T cells, blood lymphocytes, in monocytes, and macrophages
(Lustig et al., 2001, Peng et al., 2004; Galvis et al., 2006; Kawashim et al., 2007). However, the
functioning of α9α10 nAChRs in the immune cells is not clear.
1.9.

Animal Experimental Models of Colitis

Inflammatory bowel disease (IBD), includes Crohn’s disease (CD) and ulcerative colitis (UC),
results from chronic dysregulation of the mucosal immune system in the gastrointestinal tract,
and it is widely accepted that genetic, environmental, and immunological factors are involved.
Although the pathogenesis of IBD remains unclear, animal models of intestinal inflammation
have provided critical perceptions and investingating various factors involve into the
pathogenesis of colitis (Blumberg et al., 1999; Strober et al., 2002) and evaluating different
therapeutic agents. Several models of experimental colitis that demonstrate various
pathophysiological aspects of the human IBD have been described such as dextran sodium
sulfate (DSS), trinitrobenzene sulfonic acid (TNBS), acetic acid, indomethacin, and oxazoloneinduced colitis models. Here, we induced colitis in mice using dextran sulfate sodium (DSS)
which is one of the best described models of UC and a widely used animal model of colitis. It
has been used over 20 years (Ohkusa et al., 1985) due to its simplicity. In addition, it has some
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advantages over other experimental colitis models; for instance, different stages of the disease
conditions, acute, chronic, or relapsing condition can be induced by simply modulating DSS
concentration in the drinking water (animals stress-free handling) and importantly shows some
resemblance of human UC in both clinical (body weight loss, loose stool, bloody diarrhea or
rectal irritation and hematochezia) and histopathologic findings (Okayasu et. al., 1990; Takizawa
et. al., 1991; Cooper et al., 1993; Gaudio et. al., 1999), and is characterized by an excessive T
helper 2 (Th2) cell response (Targan and Karp, 2005). The responsiveness of the DSS-induced
colitis model to conventional therapeutic agents for human UC supports its suitability as a model
of human UC and help to translate basic research to clinical practice (Böjrck et. al., 1997).
However, using DSS-induced colitis model, various factors may affect the responsiveness to
DSS; such as, concentration of DSS used in the experiment (Egger et al., 2000), duration of
exposure, molecular weight of DSS (Kitajima et al., 2000; Hirono et al., 1983), animals strain
and sex differences (Mahler et al., 1998). Thus, all these factors should be considered during
study design before conducting the experiment.
1.10. Using Genetically Modified Animals: a complementary approach to study the role of
nAChR subtypes in murine colitis model
The use of knock-out mice for different nicotinic receptor subunits is an attractive approach to
overcome the limitation of the availability and/or selectivity of nicotinic receptor ligands.
Importantly, this approach helps to elucidate the role of specific nicotinic receptor subtypes and
provides a powerful tool to confirm results derived from pharmacological studies. . Overall, the
use of genetically modified animals and knockout technology offers many advantages that
cannot be achieved through the use of pharmacological agents that can be utilized as
complementary tools to insight the specific functional role of certain nicotinic receptor subunit.
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The KO mouse is typically engineered using mouse embryonic stem (ES) cells from the 129/Sv
inbred mouse. The gene of interest is inactivated by replacement of coding sequences essential
for gene function with a neomycin cassette. Through homologous recombination, the normal
gene on the chromosome is replaced with the targeted cassette, thus “knocking out” the gene
function. These engineered stem cells from the 129/Sv mouse that contain the homologous
recombination construct are then injected into C57Bl/6 (B6) mouse blastocysts, and implanted
into a foster mother; thus, the pups born from this event are composed of cells from a B6 embryo
and 129/Sv stem cells. The resulting chimeric mice that contain the mutated embryonic stem
cells are then mated with B6 mice to allow the mutation of the KO allele to pass onto the next
generation, the resulting mice will be heterozygote that can be inter bred to generate
homozygous mutant KO mice and ultimately generate KO mice in later generations. To date,
several nAChR KO mice have been generated and the phenotypes have been characterized. Here
in our studies we used α5 (Salas et al., 2003), α7 (Orr-Urtreger et al., 1997), β2 (Picciotto et al.,
1995). One major limitation to KO studies is the compensatory mechanisms in knockout mice,
and the occurrence of developmental requirements that may occur as a result of gene deletion,
and can interfere with interpretation of results. It may be difficult to determine if the mouse
phenotype is a result of the gene deletion. The backcrossed of these knockout mice for 10
generations with C57BL/6 mice could help reduce the possibility that mixed genetic of mutant
mouse background.
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1.11. Dissertation Objectives
Using DSS-induced experimental colitis model in male C57BL/6J mice:
-

To characterize the dextran-sulphate sodium (DSS)-induced colitis model in mice.

-

To investigate the effect of the main active substance of tobacco, nicotine and its
main metabolites, cotinine, in a DSS-induced colitis model.

-

To examine if dose and route of nicotine administration have a role in ameliorating
DSS-induced colitis model.

-

To examine the role of α7 nAChRs in mouse DSS-induced colitis model using
pharmacological tools by examing the effect of chronic treatment of α7 agonists,
PHA-543613, choline and the positive allosteric modulator for α7 nicotinic receptor,
PNU 120596 and confirm our results using genetically modified animals, α7 KO mice.

-

Finally, to assess the specificity of the involvement of α7 nAChRs by investingating
the role of non-α7 nAChRs including α5, α9, α10 and β2 nAChRs in DSS colitis
model.
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CHAPTER TWO
Materials and Methods
2.1. Animals
Male C57BL/6J, α5, α7 knockout mice were purchased from Jackson Laboratories (Bar Harbor,
ME). Mice null for the β2 subunit were provided from Institut Pasteur (Paris, France). The null
mice and their wild-type littermates were bred in an animal care facility at Virginia
Commonwealth University (Richmond, VA, USA) and are maintained on a C57Bl/6 background
and have been backcrossed to at least N10. For all experiments, mutants and wild type controls
are obtained from crossing heterozygote mice. This breeding scheme allows us to rigorously
control for any anomalies that may occur with crossing solely mutant animals. Male animals
were 8-10 weeks of age at the start of the experiments, weighing 25-30 g and were group-housed
in a 21°C humidity-controlled Association for Assessment and Accreditation of Laboratory
Animal Care-approved animal care facility with ad libitum access to food and water. Mice were
housed under standard conditions for a minimum of 1 week before experimentation. Experiments
were performed during the light cycle and were approved by the Institutional Animal Care and
Use Committee of Virginia Commonwealth University.
2.2. Drugs

(-)-Nicotine hydrogen tartrate salt [(−)-1-Methyl-2-(3-pyridyl) pyrrolidine (+)-bitartrate salt] and
(-)-cotinine were purchased from Sigma-Aldrich Inc. (St. Louis, MO). DSS (molecular weight
36-50,000 kilodaltons) was obtained from ICN Biomedicals Inc. (Aurora, OH). Nicotine doses
are expressed as the free base of the drug. PHA-543613,(N-[(3R)-1-Azabicyclo[2.2.2]oct-3yl]furo[2,3-c]pyridine-5-carboxamide Dihydrochloride) and PNU-120596 (1-(5-chloro-2,4-
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dimethoxy-phenyl)-3-(5-methyl-isoxanol-3-yl)-urea) were obtained from the drug supply
program of the National Institute on Drug Abuse (Rockville, MD). PHA-543613 was dissolved
in physiological saline (0.9% sodium chloride) and administered by subcutaneously twice daily.
PNU-120596 was suspended in a vehicle of absolute ethanol, Emulphor-620 (Rhone-Poulenc,
Inc., Princeton, NJ), and saline at a ratio of 1:1:18 and administered by i.p. injection once daily at
a volume of 10 ml/kg body weight unless noted otherwise. Doses are expressed as the free base
of the drug. Choline chloride (Sigma-Aldrich) was dissolved in the drinking water and given
orally. DSS at different concentrations was dissolved in the drinking water and given orally. The
doses of PHA-543613, PNU 120596, and choline chloride were chosen based on previous data
(Wishka et al., 2006; Krafft et al., 2012; Hurst et al., 2005; Ghia et al., 2009). α-Conotoxin-RgIA
(α-RgIA), a selective α9* antagonist, (provided from Dr Michael McIntosh, University of Utah)
(0.1, 0.2, and 0.02 mg/kg once daily) treatment started 3 days before and for 7 days after the
induction of colitis. α-RgIA, was dissolved in physiological saline (0.9% sodium chloride) and
administered by subcutaneous (s.c.) injection at a volume of 10 ml/kg body weight. Molecular
mass of RgIA is 1572 daltons. In addition, we conducted a dose-response curve for each drug in
DSS-induced colitis model in mice.
2.3. Dextran Sulphate Sodium (DSS)-induced colitis model:
DSS was added to the drinking water at different concentrations (in % w/v) for 7 days in most
experiments. On day 8, mice received drinking water without DSS. Controls were all age- and
time-matched and consisted of mice that received regular tap drinking water for the
corresponding number of days. Each treatment group consisted of 8-10 mice.
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2.4. Assessment of the Severity of Colitis: Disease Activity Index
Disease Activity Index (DAI) scores historically have correlated well with the pathologic
findings in a DSS-induced model of IBD (Cooper et al., 1993). DAI is the combined score of
four clinical parameters, including a) weight loss, b) stool consistency, c) rectal irritation, and d)
blood in the stool. Scores were defined as follows: for weight: 0, no loss; 1, 5%–10%; 2, 10%–
15%; 3, 15%–20%; and 4, 20% weight loss; for irritation around the anal area; 0, normal; 1, mild
irritation; 2, moderate irritation; 3, severe irritation; for stool: 0, normal; 1, mild loose stool; 2,
moderate loose stool and 3, diarrhea; and for bleeding: 0, no blood; 1, presence of blood
(Hemoccult II positive; Beckman Coulter, Fullerton, CA); and 2, gross blood. DAI symptoms
were recorded same time of every day and scored from days 0–8 in blinded manner to the
treatment and mouse genotypes. Total DAI score ranged from 0-12. On day 8, after replacing the
DSS with water, the mice were sacrificed and the abdominal cavity was opened, the entire colon
was immediately removed and the colon length (cm) measured.
2.5. Colonic Histology Assessment
Seven days after the beginning of the DSS treatment, two-three mice of each group were
sacrificed and the colon was removed. Formalin-fixed colon segments were paraffin-embedded
and 3-µm sections were stained with haematoxylin-eosin (H&E). Colonic damage was scored
based on a published scoring system that considers architectural derangements, epithelium
changes, goblet cell depletion, ulceration, and degree of inflammatory cells infiltrate in a blinded
fashion (Iba Y et al., 2003). The histological scoring system was used to evaluate the degree of
colitis. The total histological score ranged from 0 to 12, which represented the sum of scores
from 0 to 3 (0= none, 1= 0-5 %, 2= 5-10%, 3= > 10%) for loss of epithelium, (0= none, 1= 0-
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10 %, 2= 10-20%, 3= > 20%) for crypt damage, (0= none, 1= mild, 2= moderate, and 3= severe)
for each of depletion of goblet cells and infiltration of inflammatory cells. Each section was
scored for each feature separately by establishing the product of the grade for that feature and the
percentage involvement in the loss of epithelium and crypt damage features (in a range from 0 to
3 for each feature). The number of inflammatory cells infiltration in 10 randomly selected power
fields (40X) was counted and the number per 10 fields was calculated. The scores were assigned
by one experienced histopathologist with no knowledge of the group being examined in each
analysis. The histological colitis score of individual mice represents the sum of the different
histological subscores. Light microscope images were acquired with an Axioscope AX10
microscope and Axioviosion 4.6 software (Carl Zeiss, Inc.). Mean ± SE, n=3 animals were used
per group.
2.6. Assessment of Colonic Myeloperoxidase (MPO) Activity:
The colonic tissues were homogenized with a homogenizer in phosphate buffered saline (PBS)
for the assessment of MPO. Tissue samples were homogenized in 100 mM sodium acetate (pH
6.0) containing 0.5% hexadecyl trimethyl ammonium bromide and 5 mM EDTA. The
homogenate was briefly sonicated, and then centrifuged at 13000 rpm for 10 min at 4° C. The
supernatant was then added to a homogenizer solution in 96 well plate. 75 µl of 3,3’5,5’tetramethylbenzidine (TMB) substrate were added to each well and the plates were incubated for
2 min; 50 µl of stop solution (2N H2SO4) were then added. The plates were read at 450 nm
within 30 min. For each mouse, a semilog curve of sample dilution vs. optical density (O.D.) was
plotted to obtain a midpoint titer. Mean ± SE, n=5-8 animals were used per group.
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2.7. Tumor necrosis factor-alpha (TNF-α) Levels:
The colonic sample was homogenized in 1 mL of Tris-HCl buffer containing protease inhibitors
(Sigma-Aldrich Inc., St. Louis, MO, USA). Samples were centrifuged then centrifuged (1811 x g,
5 min) at a temperature of 4°C, and the supernatant was frozen at - 80°C until assay. The protein
concentration was determined by the Bradford assay (Bradford, 1976). Cytokine level (TNF-α)
was determined using an enzyme-linked immunosorbent assay commercial kit (Quantikine M
murine; R&D Systems, Minneapolis, MN).
2.8. Total Protein Quantification
The Bradford protein assay was used to determine the total protein content in the supernatant.
We have chosen the most widely used protein as our standard - Bovine Serum Albumin (BSA).
The assay is based on the proportional binding of the dye Coomassie to proteins. 2 µl of
supernatant was added to 750 µl of Bradford reagent (Sigma) at room temperature. The
absorbance at 595 nm was measured and the protein concentration determined using a standard
curve.
2.9. Nicotine and Cotinine Plasma Levels:
Blood samples were taken from mice receiving different protocols of nicotine: 10 days after oral
(-)-nicotine or (-)-cotinine administration in the drinking water, 2 weeks after continuous
minipump (-)-nicotine infusion (2.5 and 25 mg/kg) and 5 min after the last s.c. injection of
chronic nicotine injection (0.5 and 2 mg/kg) (Tables 4 and 5). Animals were anesthetized with
CO2, blood samples were taken by intra-cardiac puncture just before death and blood was kept in
sodium heparin blood collection tubes, and centrifuged (1400 x g, 10 min). The serum then was
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stored at - 4ᵒC. Nicotine and cotinine serum levels were measured using HPLC/MS/MS analysis.
At least 6 animals were used per group.
2.10. Nicotine and metabolites HPLC/MS/MS analysis:
Specimen extraction: To a 200 µL aliquot of whole blood, 50 µL of internal standard (ISTD)
containing 50 ng of nicotine-d4 and cotinine-d3 in methanol was added with mixing. Then 100
µL of 5M ammonium hydroxide was added to each sample followed by 2ml methylene chloride.
The samples were mixed for 2 minutes and then centrifuged (1811 x g, 5 min) at a temperature
of 4°C. The organic layer was transferred to a clean test tube. The aqueous phase was extracted
twice more with 2 mL of methylene chloride. The organic phases were combined and 500 µL of
25mM HCl in methanol was added. Samples then were evaporated to dryness under a gentle
stream of nitrogen. They were reconstituted with 100 µL of mobile phase and placed in autosample (HPLC/MS/MS) vials for analysis.
Instrumental Analysis: The HPLC/MS/MS system used was an Applied Bio systems 3200 Qtrap
with a turbo V source for TurbolonSpray with a Shimadzu SCL HPLC system controlled by
Analyst 1.4.2 software. The chromatographic separation was performed using a Hypersil Gold,
3mm X 50 mm, 5 micron (Thermo Scientific, USA). The mobile phase contained 10 mM
ammonium formate; methanol (10:90 V/V) and was delivered at a flow rate of 0.5 mL/min. The
acquisition mode used was multiple reaction monitoring (MRM) in a positive mode. Transition
ions monitored for nicotine (163>130; 163>117), nicotine-d4 (167>134), cotinine (177>80;
177>98) and cotinine-d3 (180>80). The total chromatographic separation time for each extract
injection was 2 minutes. A calibration curve ranging from 12.5 ng/ml to 500 ng/ml was
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constructed for each compound based on linear regression using the peak area ratios of the drug
to its deuterated ISTD. Cotinine-d3 also was used as the ISTD for 3-hydroxycotinine.
2.11. Statistical Analysis. Statistical analysis of all studies was performed with ANOVA. Twoway repeated-measures ANOVAs were used at the different time points. Significant overall
ANOVA were followed by Tukey’s test post hoc test when appropriate. All differences were
considered significant at *p<0.05. The GraphPad Prism® program was used for data
manipulations, graphical representations, and statistical analysis (GraphPad Software Inc., San
Diego, CA). Clinical, histological, cytokine data are presented as mean ± SE at different
treatments and time points (n=6-8 animals for clinical DSS results, n=3 per group for histological
results, n=5-8 animals for MPO and cytokine measurements).
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CHAPTER THREE
The Impact of Nicotine Route of Administration in Murine DSS-induced Colitis
Background and purpose. Studies have shown that nicotine has a positive influence on
symptoms of ulcerative colitis (UC). In the present study, we explored the effect of nicotine
treatment using different route of administrations in the DSS colitis mouse model. We also
investigated the effects of cotinine, a major metabolite of nicotine, in the model.
Experimental approach. C57BL6 male adult mice were given DSS solution at different
concentrations freely in the drinking water for 7 consecutive days after which tap water was
given on the 8th day. Disease severity, length of the colon, colon tissue histology, inflammatory
markers including colonic myeloperoxidase (MPO) activity and colonic tumor necrosis factor-α
(TNF-α) levels were then evaluated. The effect of oral, subcutaneous, infusion of nicotine, and
oral cotinine treatments were examined the DSS model. In addition, we measured the plasma
levels of the nicotine and cotinine in our treatment protocols.
Key Results. Administration of low, but not high, doses of oral nicotine in DSS-treated mice
produces a significant decreases in DAI severity, histological damage scores, as well as colonic
level of TNF-α. However, the anti-inflammatory effect of nicotine was not seen after chronic s.c.
and infusion of the drug. Differences in plasma levels of nicotine and cotinine do not seem to
account for this lack of effect. Finally, cotinine oral administration on its own failed to show a
significant effect in the DSS model of colitis.
Conclusions and Implications. Results obtained from this study highlight that dose and route of
administration play a critical role in the protective effect of nicotine in the DSS mouse colitis
model.
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3.1. Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology,
due partly to genetic susceptibility to environmental factors that misdirect the mucosal immune
system response to attack the epithelial layer of the colon causing inflammation. UC is a
remitting and relapsing inflammatory condition that results in excessive mononuclear cell and
neutrophil infiltration into mucosa and submucosa vicinities that affects primarily the distal
colon and rectum (Hanauer, 1996). Patients typically present with bloody diarrhea and passage
of pus and/or mucus that often persists for months and is accompanied by abdominal cramping
during bowel movements. Current pharmacotherapies, which include 5-aminosalicylic acid drugs
and glucocorticoids, have poor efficacy and many adverse effects that limit their use (Rosenberg
and Peppercorn, 2010). It is, therefore, highly desirable to develop more efficacious treatments
that elicit fewer side effects than presently used medications.
UC has been linked to tobacco smoking for more than three decades. For example,
smokers with UC who quit smoking experienced an increase in disease activity; however, mild
disease activity and symptom improvements were seen in ex-smokers who returned to smoking
(de Castella 1982; Motley et al., 1987; Ruda et al., 1989; Kuisma et al., 2004). Moreover,
tobacco smoking has been reported to often have a beneficial outcome on the course of activity
of UC in smokers (Boyko et al., 1988; Mokbel et al., 1998; Gheorghe et al, 2004; Höie et al.,
2007) and to decrease the need for colon surgery (Odes et al., 2001; Cosnes J, 2004). Although
cigarette smoke contains hundreds of substances, there is evidence that nicotine accounts for the
beneficial effect of smoking. However, since nicotine is metabolized to cotinine (> 80%) and
other metabolites, it is possible that these latter metabolites account, at least in part, for the
protective effect of smoking in UC.
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A number of clinical studies has been carried out in which nicotine was administered in
different formulations using patches and gums to UC patients. Nicotine has shown positive
results on disease symptomology in some trials. Nevertheless, results have been conflicting and
interpretation has been confounded by side effects experienced by individuals as a result of the
high systemic nicotine concentrations required (Pullan et al., 1994; Cosnes et al., 2004;
McGilligan et al., 2007). In addition, it has been indicated that nicotine lacks efficacy in treating
disease relapses and remission (Perera et al., 1984; Thomas et al., 1995; Ingram et al., 2005).
Thus, collectively these results indicate that, while transdermal nicotine may be effective for UC
especially in ex-smokers, its use is limited by its adverse event profile. However, it is not clear if
the delivery of nicotine through patches and gum formulations, which do not mimic the
intermittent delivery of nicotine from cigarettes, plays a role in the efficacy of the drug.
Furthermore, clinical studies conducted by Green et al., (1997) and Sandborn et al. (1997) tested
nicotine enemas, in which nicotine is applied directly to the colon, indicated that UC symptoms,
endoscopic features, and histologically-revealed damage were improved with only a few of the
patients reporting some side effects. These initial studies indicate that nicotine applied directly
to the colon, perhaps in an enema formulation, may be beneficial while causing fewer side
effects.
Similar findings with nicotine have been reported in rodent models of colitis.

For

example, oral nicotine treatment improved the macroscopic damage of experimental colitis
(Eliakim et al., 2001). Ghia et al., (2006) reported also that 20 µg/ml of nicotine in drinking
water decreased clinical signs of inflammation and reduced colonic MPO activity and TNF-α
levels in the mouse DSS model. However, chronic intraperitoneal injection of nicotine (0.25 and
2.50 µmol/kg) in DSS-induced colitis in mice failed to decrease clinical signs of inflammation,
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colonic TNF levels and histological features of the disease (Snoek et al., 2010).
In the present study, we used the DSS mouse model, one of the best described and widely
used animal models of UC since it shows some resemblance to human UC in both clinical (body
weight loss, loose stool, bloody diarrhea or rectal irritation and hematochezia) and
histopathologic findings (Okayasu et. al., 1990; Takizawa et. al., 1991; Cooper et al., 1993;
Gaudio et. al., 1999). Furthermore, the model is characterized by an excessive T helper cell
response (Targan and Karp, 2005). The responsiveness of the DSS-induced colitis mouse model
to conventional therapeutic agents for human UC supports its suitability as a model of human
UC (Böjrck et. al., 1997). We examined the effect of chronic nicotine administration using
various doses and routes of administration (subcutaneous, infusion using osmotic minipump, and
oral) in order to define the optimal route and dose that resulted in ablation of DSS-induced colitis
model in the mouse. We also tested the effect of one of the main nicotine metabolites, cotinine,
in order to garner insight as to whether it contributes to the beneficial effect of cigarette smoking
in UC patients.
3.2. Materials and Methods
See chapter 2
3.2.1. Drugs
(-)-Nicotine hydrogen tartrate salt [(−)-1-Methyl-2-(3-pyridyl) pyrrolidine (+)-bitartrate salt] and
(-)-cotinine were purchased from Sigma-Aldrich Inc. (St. Louis, MO). DSS (molecular weight
36-50,000 kilodaltons) was obtained from ICN Biomedicals Inc. (Aurora, OH). Doses are
expressed as the free base of the drug.
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3.3. Chronic nicotine treatment
DSS-induced colitis model: DSS was added to the drinking water at 1%, 2.5% and 5%
concentrations (in % w/v) for 7 days. On day 8, mice received drinking water without DSS.
Controls were all age- and time-matched and consisted of mice that received regular tap drinking
water for the corresponding number of days. Each treatment group consisted of 8-10 mice.
3.3.1. Study 1. Dextran sulfate sodium (DSS) dose response curve. Separate group of mice
were allocated to the following treatments: controls (water only), 1% DSS, 2.5% DSS and 5%
DSS for 7 days.
3.3.2. Study 2. Effect of Oral (-)-nicotine administration. Different doses of (-)-nicotine (6,
12.5, 25, 50, and 100 µg/ml) were added to the drinking water 3 days before and for 7 days along
with the induction of colitis with DSS 2.5%.
3.3.3. Study 3. Effect of s.c. (-)-nicotine administration. Saline or (-)-nicotine treatment (0.1,
0.5, 2 mg/kg) was given s.c. twice daily for 10 days. (-)-nicotine was dissolved in physiological
saline (0.9% sodium chloride) and administered by s.c. injection at a volume of 10 ml/kg body
weight. The s.c. nicotine or saline injection was administered 3 days before induction of DSS
colitis and was continued along with DSS treatment period.
3.3.4. Study 4. Effect of (-)-nicotine administration through mini pump. Nicotine was infused
for 14 days though osmotic mini pump at doses of 2.5 and 25 mg/kg/day. Mice were implanted
with Alzet osmotic mini pumps [model 2002 (14 days), Durect Corporation, Cupertino, CA]
filled with (-)-nicotine or saline solution. The concentration of nicotine was adjusted according to
animal weight and the mini pump flow rate, resulting in 2.5 and 25 mg/kg/day for 14 days. The
mini pumps were surgically implanted s.c. under sterile conditions with sodium pentobarbital
anesthesia (45 mg/ml, i.p.). An incision was made in the back of the animal, and a pump was

26

inserted. The wound was closed with wound clips, and the animal was allowed to recover before
being returned to its home cage. DSS was added to the drinking water for 7 days in the second
week of saline or (-)-nicotine minipump implantation.
3.3.5. Study 5. Effect of oral cotinine administration. Two doses of (-)-cotinine (25 and 250
µg/ml) were added to the drinking water 3 days before and for 7 days along with the induction of
colitis with DSS 2.5%.
3.4. Results
3.4.1. Characterization DSS dose response curve on colitis severity in the mouse
We first evaluated the colitis severity in the mouse DSS model. For that, we examined
the effects of 1, 2.5 and 5% of DSS concentrations in C57BL/6J mice on the disease activity
scores, colon length, colonic histological damage, colonic MPO activity and colonic TNF-α
levels.
Oral DSS administration for 7 days induced signs of colitis in C57BL/6J mice in a doserelated manner [F (3, 30) =46.12, p<0.0001] as measured by the disease activity scores (Figure 1
A-C). Mice treated with 1% DSS did not show significant differences in any of the colitis
parameters including rectal irritation, loose stool, bloody diarrhea and loss in body weight,
compared with the water-treated control group. However, both 2.5 and 5% DSS concentrations
significantly increased all clinical signs of colitis severity.

The loss of body weight was

significant on day 5 and exhibited a gradual increase in mice receiving 2.5% DSS and 5% DSS
with a ˜ 15% loss on day 8 (Figure 1 C). Similar to disease activity, the decrease in the colon
length was dose related with all DSS concentrations significantly resulting in reduction in length
compared to the water-treated control group (Figure 1 D).
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In general, the increase in the inflammatory markers MPO and the pro-inflammatory
cytokine TNF-α correlated with the severity of colitis. MPO activity was undetectable in the
control water-treated animals and was higher in mice-treated with DSS 2.5 and 5% respectively
[F (3, 14) =7.668, p=0.0029] (Figure 2 A). The level of TNF-α, an acute inflammatory marker,
was increased significantly in mice treated with 2.5 and 5 % DSS compared to the control group
[F (3, 16) = 49.46, p<0.0001] (Figure 2 B).
The histology of the colon after 7 days of DSS treatment was characterized by multifocal
changes in crypts with some areas showing focal lesions and inflammatory cell infiltration that
included neutrophils and lymphocytes. The histological damage was significantly higher in the
2.5 and 5% DSS group when compared with the control group [F(3, 36) = 36.23, p<0.05] (Figure
3 E). There were focal changes suggesting a discontinuous appearance of histological features
with varying severity of epithelial loss (Figure 3 A), shortening of crypts (Figure 3 B), depletion
of goblet cells (Figure 3 C), and inflammatory cells infiltration (Figure 3 D). The extent of the
inflammatory response also was assessed by histology of mucosal tissue using haematoxylineosin staining (Figure 4). DSS-treated mice showed extensive ulceration of the mucosa with
destruction and inflammation mainly in the mucosa; however, some inflammation to the
submucosa was seen with 5% DSS as well as shortening of the crypts, and inflammatory cell
infiltration (Figure 4 D). Since the 7-day 2.5% DSS administration protocol showed a reliable
inflammatory colitis with a low rate of mortality compared to the 5% DSS group [30% vs 75%
for 2.5% and 5%, respectively] after 7 days recovery period post-DSS (Figure 5), it was chosen
for subsequent studies with nicotine and nicotine ligands.
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3. 4. 2. Oral nicotine administration attenuates DSS-induced colitis
Oral nicotine treatment at doses of 12.5, 25 and 50 µg/ml significantly decreased disease
activity scores during the last three days of DSS disease course [F(3,48) = 6.615, p=0.0021]
(Figure 6 A). In contrast, nicotine at the highest dose (100 µg/ml) significantly enhanced disease
activity scores at day 7 and day 8 compared with the DSS-treated group as seen in the doseresponse curves and area under the curve values [F(2, 19) = 5.593, p=0.0123] (Figure 6 A & B).
A similar profile was seen with the body weight loss where the effect of nicotine was lost at
higher doses (Figure 6 C). All tested doses of oral nicotine treatments did not significantly
reverse the effect of DSS on the colon length shortening (Figure 6 D).
Oral nicotine at 25 µg/ml, a dose that attenuated DSS-induced colitis signs, reduced also
the increase in colonic TNF-α levels seen with DSS-treated mice [F(3,27) = 4.60, p=0.010]
(Figure 7 A). However, this effect was lost at the high dose of 100 µg/ml of the drug. In line
with the disease activity scores, DSS-treated mice showed a significant decrease in histological
scores after treatment with the low dose of 12.5 µg/ml of nicotine. However, this effect started
to gradually decrease with increasing doses (25 and 100 µg/ml) of nicotine (Figure 7 B).
Furthermore, nicotine oral administration at doses of 12.5 and 25 µg/ml normalized the
appearance of epithelial architectures of colonic slices and reversed the DSS-induced colonic
damage (Figure 7 E & F).
To determine if nicotine is bioavailable in our treatment protocols, the plasma levels of
the drug and its main metabolite cotinine, were measured using the lowest active dose and
highest dose of oral nicotine administration in DSS-treated mice. Oral nicotine administration
resulted in a dose-related increase in the level of plasma levels of nicotine and cotinine (Table 4)
in DSS-treated mice.
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3.4.3. Effect of subcutaneous and mini pump nicotine treatments on DSS-induced colitis
Subcutaneous nicotine treatment (0.1, 0.5 and 2 mg/kg s.c. twice daily for 10 days) was
evaluated in the DSS model. Overall, nicotine given s.c. failed to alter significantly the intensity
disease activity in the DSS-treated animals. Only the low dose of 0.1 mg/kg s.c. resulted in a
significant decrease in the disease activity on days 7 and 8 (Figure 8 A). A decrease in the area
under the curve at the same dose was observed, but it failed to reach statistical significance
(Figure 8 B) [F (3, 36) = 2.604, p=0.0668)]. Similarly, only mice injected with 0.5 mg/kg s.c.
showed a significant attenuation in the colon length shortening when compared with the vehicle
DSS-treated group [F (4, 42) = 20.76, p<0.05] (Figure 8 C). However, none of the nicotine
doses tested after chronic s.c. injection showed a significant decrease in total histological damage
score compared with DSS-treated mice (Figure 8 D). Similarly, nicotine did not reverse colonic
TNF-α levels in DSS-treated mice (Table 2). Finally, chronic administration of 0.5 and 0.1
mg/kg of nicotine increased the plasma levels of nicotine and cotinine in mice. Drug plasma
levels after nicotine administration of 0.1 mg/kg were below the level of detection (Table 4).
Chronic exposure of mice to nicotine via mini pumps infusion at doses of 2.5 and 25
mg/kg/day was assessed. Overall, nicotine given via infusion failed to alter significantly the
colitis severity of the DSS-treated animals. Only the low dose of 2.5 mg/kg/day exerted a
significant decrease in the disease activity index on day five compared with the control group
(Figure 9 A). However, no significant decrease in the area under the curve of disease activity in
nicotine-treated mice was seen at both infused doses of the drug (Figure 9 B). Similarly, nicotine
treatment failed to significantly reverse the decrease in colon length in the DSS-treated mice
(Figure 9 C). However, the low dose of nicotine infusion (2.5 mg/kg/day) showed a significant
decrease in total histological damage score compared with DSS-treated mice [F(2, 31) = 4.531,
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p=0.0188] (Figure 9 D). This effect was not observed at the high dose of 25 mg/kg/day of
nicotine. In contrast, neither dose of nicotine resulted in lowering the increase in colonic TNF-α
levels observed for DSS-treated mice [F(3, 46)=16.66, p<0.05] (Table 3). Finally, chronic
infusion administration of nicotine induced a dose-related manner an increase in the plasma
levels of nicotine and cotinine in mice (Table 4).
3.4.4. Effect of cotinine, the main metabolite of nicotine, in the DSS-induced colitis model
To determine whether cotinine, the principle metabolite of nicotine, possessed antiinflammatory effects in the colitis model, DSS-treated animals were subjected to chronic
cotinine given orally at two different doses (25 and 250 µg/ml). As shown in Figure 10, cotinine
administration neither had a significant effect on colitis severity as measured by disease activity
scores (Figure 10 A & B) nor resulted in a shortening of the colon length (Figure 10 C).
Cotinine was bioavailable since the plasma levels of the drug and its metabolite (3-OHCotinine)
(Table 5) were shown to be increased in a dose-related manner after oral administration of the
drug at 25 and 250 µg/ml.
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Figure 1

Figure 1. Colonic inflammation was aggravated after DSS exposure to mice in a doserelated manner.
(A) Disease activity index (DAI) changes among groups exposed to different doses of DSS (B)
AUC of DAI for mice in (A). (C) Percentage of body weight change for mice in (A). (D) Mean
colon length (cm) for the mice in (A). C57BL/6 mice were given different doses of DSS (1%,
2.5% and 5%) in the drinking water for 7 days. All clinical signs were assessed on daily basis for
each mouse and were averaged per day for each group. Results are expressed as mean ± SE, n=68, *p<0.05. DAI = disease activity index, AUC = area under the curve, Ctrl = water-treated
animals.
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Figure 2

Figure 2. Aggravation of inflammatory markers after 7 days of exposure to different doses
of DSS in mice.
(A) Colonic MPO activity (midpoint titer/g wet tissue) in groups exposed to different doses of
DSS (0, 1, 2.5, 5%). (B) Colonic TNF α level (pg/mg protein) for mice in (A). Results are
expressed as mean ± SE, n=6-8. *p<0.05 Ctrl = water treated group. Ctrl = water-treated mice,
MPO = myeloperoxidase activity.
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Figure 3

Figure 3. Histological scores from colons after 7 days of exposure to water or different
doses of DSS.
(A) Loss of epithelium. (B) Crypt damage. (C) Depletion of goblet cells. (D) Infiltration of
inflammatory cells. (E) Total histological damage score. Histological scores were blindly
evaluated using H&E stain of the colonic tissue sections after 7 days of water-treated control
group and DSS-treated animals. Results are expressed as mean ± SE, n=3, *p<0.05. Ctrl = water
treated group.
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Figure 4

Figure 4. Histological analysis of representative colons from mice after 7 days of exposure
to water or different doses of DSS.
(A) Appearance of control water-treated control. (B) Appearance of colon treated with 1% DSS.
(C) Appearance of colon treated with 2.5% DSS. (D) Appearance of colon treated with 5% DSS
(Haematoxylin-eosin staining of colonic tissue sections, magnification: X40, Scale bar 20µm).
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Figure 5: Survival rate of C57Bl/6 mice treated with DSS at 2.5 and 5% concentrations for
7 days then followed 7 days without DSS (recovery phase).

Figure 5. The 5% DSS-treated mice did not survive the recovery phase.
Mice received DSS (2.5 or 5%) during the acute phase (day 1-7), and replaced with tap drinking
water during the recovery phase (day 8-14). On day 11: only 33% survived of 5% DSS group,
while more than 70% survived from mice treated with 2.5% DSS.
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Figure 6

Figure 6. Oral nicotine treatment suppressed the severity of DSS-induced colitis in mice.
Effects of chronic oral nicotine treatment with various doses (6-100 µg/ml) on (A) the timecourse of DAI. (B) AUC of DAI in mice. (C) Percentage of body weight change. (D) Mean
colon length (cm). Results are expressed as mean ± SE, n=6-8, *p<0.05 compared to control
(vehicle-treated mice). Nic = nicotine.
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Figure 7

Figure 7. Oral nicotine treatment (25 and 100 µg/ml) affects colonic TNF-α levels,
histological damage score and appearance in DSS-induced colitis.
(A) Colonic TNF-α levels (pg/mg protein) in the homogenized colonic tissue samples. Results
are expressed as mean ± SE, n=6-8, *p<0.05 vs. DSS group and #p<0.05 vs Ctrl group. (B)
Histological colonic damage score in DSS-induced colitis. Representative colon sections at 7
days after induction of colitis of a control colon (C), DSS-treated mice (D), nicotine (12.5 µg/ml)
(E), nicotine (25 µg/ml) (F) and nicotine (100 µg/ml) (G). *p<0.05 vs. DSS group, #p<0.05 vs.
water control group. (Mean ± SE, n=3-5 per group). Nic = nicotine, Ctrl = water-treated group.
(Haematoxylin-eosin staining of colonic tissue sections, magnification: X40, Scale bar 20µm).
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Figure 8

Figure 8. Effect of chronic s.c. nicotine administration on the severity of DSS-induced
colitis in mice.
Effects of chronic subcutaneous nicotine treatment (0.1, 0.5 and 2 mg/kg) on (A) the time-course
of DAI. (B) AUC of DAI. (C) Mean colon length (cm). (D) Histological colonic damage score.
Results are expressed as mean ± SE, n=6-8, *p<0.05 compared to control (vehicle-treated mice).
Veh = vehicle, Nic = nicotine, s.c.= subcutaneous.
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Figure 9

Figure 9. Influence of nicotine infusion via mini pump in DSS-treated mice on DAI,
histological damage and colon length.
Effects of chronic mini pump infusion nicotine (2.5 and 25 mg/kg/day) on (A) the time-course of
DAI. (B) AUC of DAI. (C) Mean colon length (cm). (D) Histological colonic damage score.
Results are expressed as mean ± SEM of n=6-8. *p<0.05 compared to control (vehicle-treated
mice). Veh = vehicle, Nic = nicotine, MP = mini pump.
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Figure 10

Figure 10. Lack of suppression of the severity of colitis by oral cotinine.
Effects of oral cotinine (25 and 250 µg/ml) on (A) the time-course and (B) AUC of DAI in mice.
(C) Mean colon length (cm). Results are expressed as mean ± SEM of n=6-8. *p<0.05 compared
to control (water-treated mice).
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Table 1. Daily fluid volume consumption.
There was no difference in the daily fluid volume consumption between the water (control) and
the DSS 2.5% group.
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Table 2. Effect of subcutaneous nicotine treatment on colonic TNF-α levels in DSS-treated
mice. Colonic TNF-α levels [pg/mg protein] were expressed as mean ± SE (n = 6-8) after
treatment with s.c. nicotine (0.1, 0.5 and 2 mg/kg) or vehicle. *p<0.05 compared to water group.

Treatment

Water
group

Vehicle

20 ± 3.7

78.6 ± 10.7*

Nicotine

Nicotine

Nicotine

(0.1 mg/kg)

(0.5 mg/kg)

(2 mg/kg)

82.1 ± 8.3*

68.2 ± 10.6*

89.7 ± 9.7*

TNF-α levels
(pg/mg protein)
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Table 3. Effect of chronic nicotine infusion on colonic TNF-α levels in DSS-treated mice.
Colonic TNF-α levels [pg/mg protein] were expressed as mean ± SE (n=6-8) after treatment with
chronic infusion of nicotine (2.5 and 25 mg/kg/day) or vehicle. *p<0.05 compared to water
group. The nicotine treatment at dose of 2.5 or 25 mg/kg/day were not significantely different
compared to the vehicle treated group.

Treatment

TNF-α levels

Water group

20 ± 3.7

Vehicle

73 ± 12.2*

(pg/mg protein)

44

Nicotine

Nicotine

(2.5 mg/kg/day)

(25 mg/kg/day)

103 ± 8.3*

69.2 ± 9.4*

Table 4. Summary of plasma levels of nicotine and its metabolite cotinine after chronic nicotine
treatment using s.c. injection, infusion (mini pumps) or oral routes of administration. Results are
expressed as mean ± SEM of plasma concentrations in ng/ml.

Injection

Infusion

Oral

(mg/kg)

(mg/kg/day)

(µg/ml)

0.5

2

2.5

25

25

100

Nicotine
(ng/ml)

51 ±
4.7

163 ± 12

13 ±
1.5

97 ± 89

18 ± 7.4

27.5 ±
12

Cotinine
(ng/ml)

45 ±
6.5

97 ± 7

23 ± 5

282 ±
210

32 ± 7

240 ±
61
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Table 5. Summary of plasma levels of cotinine after chronic oral cotinine treatment. Results are
expressed as mean ± SEM of plasma concentrations in ng/ml.
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CHAPTER FOUR
THE ROLE OF α7 NICOTINIC RECEPTORS IN MOUSE DSS COLITIS MODEL
4.1. Introduction
Ulcerative colitis (UC) is an idiopathic, chronic, autoimmune disease characterized by
mucosal inflammation primarily affects the colon and the rectum (Hanaue, 1996). Curiously,
various studies have reported that cigarette smoking may have beneficial effects on UC (Harries et
al., 1982; Boyko et al., 1988; Van Dijk et al., 1995; 1998; Gheorghe et al, 2004; Höie et al., 2007).
In addition, nicotine patches and enemas have shown positive results on disease symptomology of
UC in some clinical studies (Srivastava et al., 1991; Guslandi and Tittobello, 1998; Green et. al.,
1997; Sandborn et al., 1997). In experimental animal models of colitis, nicotine has been shown
to be effective after oral administration in the treatment of intestinal inflammation (Qiu et al., 1997;
Eliakim et al., 1998; Sykes et al., 2000; Ghia et al., 2006). Several in vivo and in vitro evidence
suggest that α7 nicotinic acetylcholine receptors (nAChRs) may mediate the anti-inflammatory
effects of nicotine (Wang et al., 2003; de Jonge et al., 2005; Ghia et al., 2009).
Recent studies shown that α7 nAChRs can regulate inflammation primarily through the vagus
nerve acting as an endogenous “cholinergic (nicotinic) anti-inflammatory pathway”. This system
ameliorates inflammation by regulating the production of pro-inflammatory cytokines mainly
through activation of α7 nAChRs on macrophages surface (Borovikova et al., 2000; Tracey et al.,
2001; Wang H et al., 2003, 2004; de Jonge et al., 2005; Ulloa, 2005). Studies reported that vagus
nerve activation attenuates intestinal inflammation via α7 nAChRs in animal models of
postoperative ileus and experimental colitis (de Jonge et al., 2005; Ghia et al., 2006; 2007).
Abdrakhmanova et al., (2010) showed that α7 nAChRs is critical in suppressing hyper excitability
of inflamed colonic sensory neurons from DSS-colitis mice.
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In the view of this evidence for an important role of α7 nAChRs in inflammation, it was
expected that α7 nAChR agonists would ameliorate colonic inflammatory diseases. However,
Snoek et al., (2010) recently reported that although selective α7 nAChR agonists reduced cytokine
responses in vitro, they worsened the effects of DSS-induced colitis or were ineffective in those of
TNBS-induced colitis. These surprising results prompt us to reevaluate the role of α7 nAChR in
colonic inflammation in mice. Many experimental factors such as the dose used, type and receptor
efficacy of α7 nAChR agonist tested, administration method, disease severity and disease model,
may explain this unexpected results. We therefore explored the role of some of these factors on
the efficacy of α7 nAChR agonists in a mouse colitis model. We first assessed the role of α7
nAChR in the development of colitis using α7-knockout mice in the DSS model. We then tested
the effects of α7 nAChR activation on colitis using selective α7 full agonists including PHA543613 given systemically (Wishka et al., 2006) and choline given orally (Alkondon et al., 1997;
Albuquerque et al., 1998; Fayuk and Yakel, 2004). We also evaluated the effects of PNU-120596,
a type II α7 nAChRs positive allosteric modulator (PAM) in the DSS model. PAMs, in principle,
can enhance endogenous α7 nAChR functions without altering the temporal integrity of
neurotransmission or interacting directly with the α7 nAChR binding site. This property would
allow enhancing a potential endogenous α7-mediated anti-inflammatory tone activated in the
colitis model.

The use of PNU-120596 would also help investigating the role of receptor

desensitization since type II PAMs cause a dramatic slowing of receptor desensitization (Hurst et
al., 2005; Bertrand and Gopalakrishnan, 2007; Sitzia et al., 2011).
4.2. Materials and Methods
For more details see Chapter 2.
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4.2.1. Study 1: DSS-induced colitis model in α7 KO and WT nAChR mice.
DSS 2.5% (wt/vol) was added to the drinking water of wild-type and α7 KO nAChR mice for 7
days. On day 8, DSS was replaced with normal drinking water. Controls were all age- and timematched and consisted of mice that received regular tap drinking water only for the
corresponding number of days. The experimenter was blinded to the mouse genotype.
4.2.2. Study 2: Effect of chronic PHA-543613 and choline treatment in DSS-induced colitis
model. Male C57BL/6J mice pre-treated with either PHA-543613 (2, 8, and 20 mg/kg s.c. twice
daily) or vehicle. A separate group of mice were treated with oral administration of choline (10,
40, and 80 µg/ml) in the drinking water 3 days before adding the DSS, and for 7 days along with
the induction of colitis with DSS 2.5%. On day 8, DSS was replaced with normal drinking water.
4.2.3. Study 3: Effect of chronic PNU-120596 treatment in DSS-induced colitis model. Male
C57BL/6J mice pre-treated with either PNU-120596 (1, 3, and 6 mg/kg i.p. once daily), or
vehicle, started 3 days pre-DSS treatment and for 7 days along with the induction of colitis with
DSS 2.5%. On day 8, DSS was replaced with normal drinking water.
4.3. Results
4.3.1. DSS-induced colitis in α7 KO mice
In this experiment we assessed the progress of the clinical parameters during the DSS
treatment in mice lacking α7 nicotinic receptors and their littermates’ wild type. α7 KO mice
treated with 2.5% DSS displayed a significant increase in inflammation as expressed in the disease
activity index value starting from day 5 till day 8 of the experiment [t(8)=2.85, p=0.0213] (Figure
11 A) and in the area under the curve [t(9)=5.788, p=0.003] (Figure 11 B) compared with the WT
DSS-treated mice. Both α7 KO and WT DSS-treated mice displayed a significant loss of body
weight, especially α7 KO from the control water-treated mice only (Figure 11 C). The decrease in
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the colon length was significantly different between α7 KO and WT DSS-treated mice, even more
significant in α7 KO against water-treated control group [F(2, 19)= 117.6, p<0.0001] (Figure 11
D). To assess the extent of inflammation in the colon, we evaluated the histological damage score
and TNF-α colonic levels. The representative of colon histological damage changes were
expressed as the total histological change score (Figure 12 A). α7 KO mice treated with DSS
showed a significant increase in colonic total histological damage score versus the WT DSS and
the water-treated control group, [F(2, 47) = 39.24, p<0.001] (Figure 12 A). The histological
appearance of the colon after 7 days of DSS treatment in the WT mice was characterized by
multifocal changes in the crypts and some areas showed focal lesions, depletion of goblet cells and
inflammatory cell infiltrates, including neutrophils and lymphocytes; however, these changes with
epithelial destruction were seen more shortening of the crypts, inflammatory cell infiltrates,
extensive ulceration and the inflammation was mainly in the mucosa, and submucosal in colons
from the α7 KO DSS-treated mice (Figure 12 B).
Next, we measured colonic TNF-α level to observe the influence of α7 nicotinic receptor
subunit on colonic inflammation in DSS-induced colitis. In the line with the worsen in the clinical
parameters and histological damage score in α7 KO DSS-treated mice. The α7 KO DSS-mice
showed significant elevated colonic TNF-α levels, approximately 1 fold increased compared to
WT DSS-treated mice [F(2, 39) = 32.64, p<0.001] (Figure 12 C).
4.3.2. Effect of α7 nAChR agonists and PAM in DSS colitis model:
4.3.2.1. Effect of PHA-543613 on DSS-induced colitis model in mice
Treatment with twice daily of s.c. PHA-543613, a selective α7 nAChRs agonist. At low dose of
2 mg/kg does not affect either clinical parameters of colitis severity (Figure 13 A and B) or the
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colon length (Figure 13 C); however a higher dose of 8 mg/kg significantly decreased disease
activity index scores on day 6, 7, and 8 compared to DSS-treated group [F(2, 16) = 4.051,
p=0.0377] (Figure 13 A), and in the area under the curve value as well [F(3,30) = 5.403,
p=0.0043] (Figure 13 B). In addition, at that dose, PHA-543613 was able to reverse the
shortening of the colon length of DSS-treated group [F(3, 19) = 7.495, p=0.0017] (Figure 13 C).
As the dose increased to 20 mg/kg, PHA-543613 worsen the disease activity and shortened the
colon length in the DSS-treated mice. PHA-543613 at 8 and 20 mg/kg did not reduce the
increase in colonic TNF-α levels seen with DSS-treated mice (Figure 13 D).
In this experiment we also assessed the effects of PHA-543613 on the colonic histological
damage in the DSS-treated mice. PHA-543613 at both doses (8 and 20 mg/kg) has no effect on
the total histological damage score induced by DSS treatment (Figure 14 A). Figure 14 B,
showed histological appearance of the colon sections with H & E stain after PHA-543613
treatment in DSS-treated mice. The DSS-treated animals were showed ulceration and destruction
of the mucosal architecture with inflammatory cells infiltrate of polymorphonuclear leukocytes
including numbers of macrophages and lymphocytes were the inflammation was mainly in the
mucosa, and more shortening of the crypts (Figure 14 B, b). However, PHA-543613 treatment at
8 and 20 mg/kg had no effect on the total histological damage score compared with vehicle DSStreated animals, at high dose of 20 mg/kg, PHA-543613 produced extensive epithelial and
architecture destruction mainly in the mucosa and submucosa with inflammatory infiltrates
(Figure 14 B, c and d).
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4.3.2.2. Effect of Choline on DSS-induced colitis model in mice
We then tested the effect of another α7 nAChRs agonist, choline given in the drinking water. As
seen in Figure 15 A & B, low dose of oral choline treatment (10 µg/ml) has no significant effect
on the severity of clinical parameters of DSS-induced colitis model (Figure 15 A & B) or the
shortening of the colon length (Figure 15 C). However, choline at higher dose of 40 µg/ml,
significantly decreased disease activity index values on day 7 and 8 compared to the DSS-treated
group [F(3, 24) = 4.818, p=0.0092] (Figure 15 A), and in the area under the curve as well [F(3,
23) = 3.15, p=0.044] (Figure 15 B). In addition, that dose was able to reverse the shortening of
the colon length of DSS-treated group [F(3, 20) = 7.812, p=0.0012]. As the dose increased to 80
µg/ml, the protective effect of choline on disease activity and colon length disappeared in the
DSS-treated mice (Figure 15 A, B & C). Both doses (40 and 80 ug/ml) of choline did not reduce
the increase in colonic TNF-α levels seen with DSS-treated mice (Figure 15 D).
Interestingly, choline treatment at 40 and 80 µg/ml significantly decreased the total
histological damage score of the colon compared to the vehicle DSS-treated group [F(2, 97) =
11.43, p<0.001] (Figure 16 A). As seen in Figure 16 B, the DSS-treated animals showed
destruction of the mucosa, and extensive inflammatory cell infiltrates (b) as compared to the
water-control (a) group. Choline at 40 and 80 µg/ml reversed the histological damage and
normalized the epithelial architecture of the colon (Figure 16 B; c and d, respectively).
4.3.2.3. Effect of α7 nAChR positive allosteric modulator (PAM) in DSS colitis model:
As with PHA-543613 and choline, low dose of PNU-120596 treatment (1 mg/kg, i.p.) did not
reverse the DSS-induced colitis as measured by the disease activity index scores (Figure 17 A &
B). However, at dose of 3 mg/kg, PNU-120596 significantly decreased disease activity index
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scores on day 5, 6, 7 and 8 compared to DSS-treated group [F(3, 24) = 8.01, p=0.0007] (Figure
17 A). In addition, at this dose, it significantly reduced the area under the curve of disease
activity index score compared with vehicle DSS-treated mice [F(3, 18) = 3.341, p=0.0425]
(Figure 17 B). As the higher dose of 6 mg/kg, the protective effect of PNU-120596 on disease
activity disappeared in the DSS-treated mice (Figure 17 A & B).
None of the PNU-120596 doses tested did reduce the increase in colonic TNF-α levels seen
with DSS-treated mice (Figure 17 D). However, PNU-120596 treatment at 3 mg/kg significantly
decreased the total histological damage score in DSS-treated mice [F(2, 67) = 3.88, p=0.0254]
(Figure 18 A). At a higher dose of 6 mg/kg, PNU 120596’s effects on the total histological score
failed to reach statistical significance. As shown in Figure 18 B, the extensive ulceration of the
mucosa and increase in inflammatory cell infiltrates induced by DSS was reversed by PNU120596 treatment (c).
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Figure 11

Figure 11. Colonic inflammation was aggravated after DSS exposure in α7-deficient mice.
(A) Clinical evaluation of disease activity index of α7 wild type and Knock-out mice treated with
2.5% DSS in time-course manner. The DAI values were computed as described in detail in
Methods. (B) Area under the curve of DAI. (C) Percentage of body weight change during DSS
treatment period. (D) Colon length (cm) after DSS treatment. All clinical signs were assessed on
daily basis for each mouse and were averaged per day for each group. Results are expressed as
mean ± SE, n=6-8, *p<0.05. DAI = disease activity index, AUC = area under the curve, Ctrl =
water-treated animals.
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Figure 12

Figure 12. Histopathologic changes in colonic tissues and colonic TNF α level following 1
week of dextran sulphate sodium administration in α7 deficient mice.
(A) Histological damage score significantly increased in colon from α7 KO mice. (B) The histological
appearance of the colon after DSS treatment in α7 WT and KO mice. Some epithelial architectural
destruction with minimal submucosal inflammation in colonic tissue of wild type mice. In the α7 KO
mice colon, shown extensive mucosal and submucosal injury with inflammatory infiltrate in the mucosa
and submucosa. Histology alteration in mucosal tissue assessed using haematoxylin-eosin staining, (H&E
staining; magnification X20). (Mean ± SE, n=6-8, p<0.05). (C) TNF α level [pg/mg protein], an acute
inflammatory marker, was measured by enzyme-linked immunosorbent assay (ELISA). DSS induced
colitis significantly increased the TNF α level in the homogenized colonic tissue especially in α7 deficient
mice samples. (Mean ± SE, n=3 per group, p<0.05). Ctrl = water-treated animals.

55

Figure 13

Figure 13. Effect of PHA-543613 on DAI and inflammatory markers in C57Bl/6 mice with
DSS colitis. Effect of chronic PHA-543613 treatment on (A) the time-course of Disease activity
index. (B) Area under the curve of disease activity index in mice. (C) Mean colon length (cm).
(D) Colonic TNF-α levels (pg/mg protein) in the homogenized colonic tissue samples. Results
are expressed as mean ± SE, n=6-8, *p<0.05 compared to Veh. #p<0.05 vs. Ctrl in (C) and vs.
Veh in (D). Ctrl = water-treated animals, Veh = vehicle DSS-treated mice, s.c.= subcutaneous.
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Figure 14

Figure 14. Histological analysis of representative colons from C57Bl/6 mice after 7 days of
exposure to water, vehicle, or PHA-543613 treatment.
(A) The total histological colon damage score after PHA-543613 in C57Bl/6 mice. (B)
Appearance of a control colon (a), DSS-treated mice (b), and colon from PHA-543613
treatments (8 and 20 mg/kg; c and d respectivily) in DSS-treated mice. (Haematoxylin-eosin
staining of colonic tissue sections, magnification: X40, Scale bar 20µm). Results are expressed
as mean ± SE, n=3, #p<0.05 vs. Ctrl. Ctrl = water-treated animals, Veh = vehicle DSS-treated
mice.
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Figure 15

Figure 15. Chronic oral choline treatment suppressed the severity of DSS-induced colitis in
mice.
Effect of oral choline treatment on (A) the time-course of disease activity index, (B) Area under
the curve of disease activity index, (C) Mean of colon length (cm). (D) Colonic TNF-α levels
[pg/mg protein] in the homogenized colonic tissue samples. Results are expressed as mean ± SE,
n=6-8, *p<0.05 vs. DSS group and #p<0.05 vs Ctrl group. Ctrl = water-treated animals, Veh =
vehicle DSS-treated mice, po = oral.
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Figure 16

Figure 16. Histological analysis of representative colons from C57Bl/6 mice after 7 days of
exposure to water, vehicle, or choline treatment in C57Bl/6 mice with DSS colitis.
(A) The total histological colon damage score after oral choline treatment in mice. (B)
Histological appearance of a control colon (a), DSS-treated mice (b), oral choline (40 µg/mL) in
DSS-treated mice (c), oral choline

(80 µg/mL) treatment in DSS-treated mice (d).

(Haematoxylin-eosin staining of colonic tissue sections, magnification: X20). Results are
expressed as mean ± SE, n=3, #p<0.05 vs. Ctrl. Ctrl = water-treated animals, Veh = vehicle
DSS-treated mice.
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Figure 17

Figure 17. Effect of PNU-120596 on DAI, colonic TNF-α level and colon length in C57Bl/6
mice with DSS colitis.
Effect of PNU-120596 treatment on (A) the time-course of disease activity index in DSS-treated
mice. (B) Area under the curve of disease activity index, (C) Mean of colon length (cm). (D)
Colonic TNF α level [pg/mg protein] in the homogenized colonic tissue samples. Results are
expressed as mean ± SE, n=6-8, *p<0.05 vs. Veh. #p<0.05 vs. Ctrl. Ctrl = water-treated animals,
Veh = vehicle DSS-treated mice.
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Figure 18

Figure 18. Influence of PNU-120596 on histological damage score in C57Bl/6 mice with DSS
colitis (A) The total histological colon damage score after chronic PNU-120596 treatment in
DSS-treated mice. (B) The histological appearance of normal colon (a), vehicle DSS-treated
mice (b), PNU-120596 (3 mg/kg) in DSS-treated mice (c), PNU-120596 treatment (6 mg/kg) in
DSS-treated mice (d). Results are expressed as mean ± SE, n=3 per group, p<0.05.
(Haematoxylin-eosin staining of colonic tissue sections, magnification: X40, Scale bar 20µm).
#p<0.05 vs. Ctrl group, and *p<0.05 vs. Veh group. Ctrl = water-treated animals, Veh = vehicle
DSS-treated mice.
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CHAPTER FIVE

Role of non-α7 Nicotinic Receptors in Experimental Colitis
5.1. Overview
Nicotine exerts its effect through acting on various subtypes of nicotinic receptors in multiple
sites, centrally and peripherally. As described before in Chapter 1, these nicotinic receptors are
express in the CNS, PNS, and non-neuronal tissues, such as immune cells. Human lymphocytes
express mRNA for α3, α4, α5, and β4 nAChR subunits (Hiemke et al., 1996; Mihovilovic et al.,
1998; Mihovilovic and Roses, 1991, 1993). Human mononuclear leukocytes express mRNAs
encoding α2 and α5 nicotinic subunits (Sato et al., 1999). α9 and α10 nicotinic subunits have
restricted anatomical tissue distribution profile among the nicotinic receptors. While they have
not been detected in the brain and spinal cord (Elgoyhen et al., 2001; Sgard et al., 2002), they are
expressed in human T cells, blood lymphocytes, monocytes, macrophages (Lustig et al., 2001,
Peng et al., 2004; Galvis et al., 2006; Kawashim et al., 2007), and in dorsal root ganglion (DRG)
neurons (Lips et al., 2002).
Nicotinic receptor subunits are also expressed in the ENS. For example, mRNA for α3, α5, β2
and β4 have been detected in the myenteric plexus of large intestine and α3, α5 and β4
expression in some ganglia of the submucosal plexus of large intestine in rat; however, there was
no evidence for expression of α4, α6 and β3 mRNA in these tissues (Garza et al., 2009).
Furthermore, nicotinic receptors have been identified in colonic epithelial HT29 cells, including
α3, α5 nAChR subunits (Summers et al., 2003).
The distribution pattern of these various non-α7 nicotinic receptors suggests a possible role for
them in the process of colitis.
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One promising target is α9 and α10 nicotinic acetylcholine receptor especially after the
discovery of a novel selective α9α10 conotoxin antagonist. α-Conotoxins are small neurotoxic
disulfide rich peptides derived from the marine cone snails venom of Conus species (Terlau and
Olivera, 2004). Alpha-conotoxin RgIA (α-RgIA) is one of three reported α-conotoxins that block
the α9α10 nicotinic receptors and is the most potent α9α10 nAChR subtypes antagonist with an
IC50 5.2 nM in Xenopus oocytes (Ellison et al., 2006; Vincler et al., 2006; Nevin et al., 2007).
Interestingly, nicotine acts as an antagonist of rats α9 and α9α10 nAChRs (Elgoyhen et al., 1994,
2001; Sgard et al., 2002; Verbitsky et al., 2000). Recent studies have provided evidence that
administration of α9α10 selective α-conotoxin antagonists produce antinociceptive and antiinflammatory effects in neuropathic and tonic inflammatory pain animal models (McIntosh et al.,
2009; Vincler et al., 2006; Vincler and McIntosh, 2007). Immune cells seem to mediate the antiinflammatory effect of α9α10 nAChRs antagonist. Indeed, blockade of α9α10 nAChRs in
chronic constriction injury animals showed a decrease of lymphocytes and macrophages at the
site of nerve injury (Vincler and McIntosh, 2007; Vincler et al., 2006). The activation of the
functional cholinergic receptors in leukocytes might mediate the nicotinic anti-inflammatory
pathway through these immune cells. While the function of α9α10 nAChRs in the auditory
system has been well characterized (Elgoyhen AB et al., 2001), little is known regarding the
function of α9α10 nAChRs in immune cells and inflammation. The α9α10 nAChR selective
antagonist, α-conotoxin RgIA, enabled us to explore the role for α9* nAChRs in animal DSS
colitis model.
Here, because of the expression and distribution of non-α7 nicotinic receptors in peripheral
nervous system and non-neuronal tissues; we examined the role of α5 and β2 nAChR subunits
using α5- and β2-deficient nicotinic subunits KO mice using DSS-induced colitis model. In
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addition, we explored the role of α9 nAChR subtypes by testing the effect of α-conotoxin RgIA,
a α9α10 nAChR selective antagonist, in C57Bl/6 DSS-treated mice.
5.2. Materials and Methods.
See Chapter 2 for more details.
5.2.1. Study: Role of non-α7 nicotinic receptor (α5, β2, and α9) subtypes in DSS-induced
colitis model in mice. We induced colitis in α5 and β2 nicotinic receptor KO mice, and their
littermates wild-type nicotinic receptor male adult mice were given DSS solution freely in the
drinking water for 7 consecutive days after which tap water was given on the 8th day. α-RgIA
was administered s.c. once daily for 10 days in C57Bl/6 male mice, started 3 days pre-DSS and 7
days with DSS treatment. α-RgIA doses range (0.02, 0.1, 0.2 mg/kg). We measured the clinical
parameters every day over the time-course of the study and the colon length at the end of the
study.
5.3. Results: There were no significant differences in the disease activity scores and the area
under the curve of disease activity seen between the β2, and α5 deficient mice and their
littermates WT DSS-mice (Figure 19 A-D). In addition, colon shortening was not affected in β2,
and α5 KO subunits DSS-treated mice (Figure 19 E and F).
Repeated subcutaneous treatment with a low dose of 0.02 mg/kg of α-RgIA once daily
produced a significant decrease of disease activity score on day 8 and in the area under the curve
(Figure 20 A & B). However, this effect was lost at higher doses of α-RgIA (0.1 and 0.2 mg/kg).
Both high doses had no effect on the disease activity score. α-RgIA doses of 0.02 and 0.1 mg/kg
in DSS-treated mice did not have a significant loss of body weight compared with the vehicle
DSS-treated mice (Figure 20 C); however, at higher dose of α-RgIA (0.2 mg/kg) mice displayed
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a significant percentage of body weight loss from the DSS-treated mice on day 8. α-RgIA at any
of the tested doses had no effect on the shortening of the colon length of DSS-treated mice
(Figure 20 D).
Chronic subcutaneous α-RgIA administration at dose of 0.02 mg/kg had no effect on reducing
the total histological colonic damage score; interestingly, at higher dose of 0.2 mg/kg, α-RgIA
showed a significant decrease in total histological damage score in a dose-dependent manner
(Figure 21 A). At all tested doses, α-RgIA did not reduce the colonic TNF-α pro-inflammatory
cytokine levels; interestingly, at low dose of 0.02 mg/kg, RgIA did not increased or decreased
TNF-α levels (Figure 21 B).
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Figure 19. Clinical evaluation of non-α7 nicotinic receptor subtypes, particularly α5 and β2
in DSS-induce colitis model in mice.
(A, C) The time-course of Disease activity index (DAI). (B, D) Area under the curve of DAI. (E,
F) Colon length (cm). All clinical signs were assessed on daily basis for each mouse and were
averaged per day for each group. Results are expressed as mean ± SE, n=6-8, *p<0.05. DAI =
disease activity index, AUC = area under the curve.
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Figure 20

Figure 20. Effect of repeated subcutaneous α-RgIA administration on the severity of DSStreated C57BL/6J mice
Effects of chronic subcutaneous α-RgIA treatment (0.02, 0.1 and 0.2 mg/kg) on (A) the timecourse of DAI. (B) AUC of DAI. (C) loss of body weight, and (D) Mean colon length (cm).
Results are expressed as mean ± SE, n=6-8, *p<0.05 vs. Veh group. Ctrl = water-treated animals,
Veh = vehicle DSS-treated mice.
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Figure 21

Figure 21. Effect of repeated subcutaneous α-RgIA treatment in DSS-treated C57BL/6J
mice on histological damage, and inflammatory marker.
(A) Histological colonic damage score in DSS-induced colitis, (B) Colonic TNF-α levels (pg/mg
protein) in the homogenized colonic tissue samples. Results are expressed as mean ± SE, n=6-8,
#p<0.05 vs. Ctrl group, and *p<0.05 vs. Veh group. Ctrl = water-treated animals, Veh = vehicle
DSS-treated mice.
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CHAPTER SIX
General discussion, summary and future studies.
The identification of nicotinic acetylcholine receptors (nAChRs), their distributions, structures,
and functions increased understanding of the complexity of these receptors. The expression of
nAChRs in the enteric nervous system (ENS) and immune cells suggest that they may play an
important role in the gut regulation and inflammatory processess. Several clinical trials have
tested nicotine efficacy in UC patients in various pharmaceutical formulations, including gum,
transdermal patches, enemas (Perera et al., 1984; Lashner et al., 1990; Srivastava et al., 1991;
Guslandi and Tittobello, 1994, 1996; Pullan et al., 1994; Thomas et al., 1995, 1996; Sandborn et
al., 1997; Green et al., 1997; Ingram et al., 2005). It has been thought that nicotine alleviates UC
through acting on nicotinic receptors in the gut immune cells (Thomas et. al., 2005). The
expression of nAChRs on lymphocytes, such as T-cells play a role in immunocytes
differentiation, development, and function (Fujii et al., 2008). In addition, an earlier study
showed that CD4 T cells have a role in experimental animal model of colitis (Elson et al., 1998).
Nicotine may have possible effects on various immunocytes of the immune system. In fact,
immune cells express different nAChR subtypes. For example, α7 nicotinic receptors are present
in intestinal lamina propria lymphocytes (Kikuchi et al., 2008) which may have important role in
the pathogenesis and signaling pathway of intestinal inflammation.
6.1. DSS-induced colitis model dose-response curve in mice
Previous studies used different concentrations of DSS solution in animals (Ahmad et. al., 2000;
Araki et. al., 2000; Egger et. al., 2000). Furthermore, in the present study we demonstrated that
as the DSS concentration increased, the severity of disease increased, including bloody diarrhea,
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rectal irritation, body weight loss, and colonic histolopathology of mucosal injury (Egger et al.,
2000). In the present study, we showed that 7 days of 2.5% DSS administration in the drinking
water resulted in an acute inflammation of the colon with low rate of mortality. We showed all of
the clinical signs of disease activity manifested by the loss of body weight, bloody diarrhea,
rectal irritation, shortening of the colon, ulceration in the colonic mucosa which allows the
infiltration of inflammatory cells into the lamina propria, including neutrophils and lymphocytes.
The migration of neutrophils into the mucosa and the epithelial surface cause intestinal
inflammation. To further examine the extent of the inflammation in the colon, we measured two
inflammatory markers, colonic MPO activity and TNF α level. MPO is an enzyme in neutrophils
used as a marker of inflammation and an index of neutrophil infiltration (Bradley et al., 1982). A
reduction in the activity of this enzyme can be considered as an anti-inflammatory activity of the
given treatment. TNF α is an early pro-inflammatory mediator, and plays a critical pathological
role in the colonic inflammation. Both inflammatory markers were significantly increased after 7
days of DSS treatment in a dose-related fashion.
6.2. Influence of nicotinic dose and route of administration in mouse DSS colitis model
One of the objectives of this study was to determine the pharmacology of protective
effects of nicotine in the DSS-induced colitis mouse model. In addition, we assessed whether
cotinine, the main metabolite of nicotine, was effective in this model. The results suggest that
low doses of nicotine delivered orally, but not cotinine, are most effective in rendering a
protective effect in the mouse DSS colitis model. Our results demonstrated that the dose and
route of administration play a pivotal role in nicotine’s in vivo anti-inflammatory efficacy in the
DSS model of colitis. While the continuous infusion of a low dose of nicotine (2.5 mg/kg/day)
through mini pumps resulted in a modest and short improvement of clinical signs and
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histological damage, the effect was not observed at the higher dose of nicotine (25 mg/kg/day).
Similarly, chronic s.c. injection of low dose of nicotine at 0.1 mg/kg resulted slightly
improvement in clinical signs; however failed to reach statistical significant and at 0.5 mg/kg
resulted in a reversal of the shortening in colonic length. This effect was not observed at the
high dose of 2 mg/kg of nicotine. However, nicotine treatment in both routes of administration
did not effect a reversal in DSS-induced increase in colonic TNF-α levels. In contrast, oral
nicotine treatment attenuated dose-dependently DSS-induced colitis. The low doses of nicotine
(12.5-50 µg/ml) were shown to exert a protective effect; they resulted in a reduction in DAI and
histological architectural damage and in a reduction in colonic TNF-α levels. However, the
protective effects of nicotine in the DSS colitis model dissipated at the high dose of 100 µg/ml.
Interestingly, nicotine plasma levels increased only 1.5-fold between the doses of 25 and 100
µg/ml (Table 4) suggesting a narrow concentration-effect profile for oral nicotine in the DSS
model. Curiously, oral nicotine treatment at any of the doses tested failed to reverse significantly
the shortening in the colon length in the DSS-treated group.
The biphasic effect of chronic nicotine treatment on clinical parameters in DSS-induced
colitis in mice was not unexpected. The low doses of oral nicotine (12.5–25 µg/ml) were shown
to be protective while the higher doses were not. The low doses administered in drinking water
resulted in a reduction of DAI, histology architectural damage and colonic TNF-α levels,
whereas the high dose (100 µg/ml) resulted in an exacerbation of DSS colitis including the DAI
and the AUC. Exacerbation of DAI at high doses of nicotine was not observed in s.c. or
minipump nicotine-treated animals, suggesting a differential effect of nicotine dose and delivery
on colonic inflammation. The results indicative of protective effects of low dose of nicotine in
the drinking water were similar to those reported previously in various experimental colitis
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models in rats and mice (Qiu et al., 1997; Eliakim et al., 1998; 2001; Sykes et al., 2000; Ghia et
al., 2006). Qiu et al., (1997) demonstrated that nicotine treatment at a dose of 5 ug/ml in the
drinking water in DNBS-treated rats resulted in a significant decrease in the intestinal
inflammation; however, the inflammation was shown to increase at a dose of 50 ug/ml.
Similarly, Eliakim et al., (1998) and Sykes et al., (2000) reported that nicotine had a dual effect
on colitis in mice with low doses of nicotine being more effective at reducing the inflammation
than higher doses. This dual anti-inflammatory effect of nicotine in the form of an “inverted-U,”
has been described previously in behavioral effects of nicotine (Picciotto, 2003).
Overall, our results suggest that the route of administration of nicotine is an important
factor to consider in the treatment of colitis. The lack of a clear anti-inflammatory effect of
nicotine after s.c. and minipump infusion in the DSS model, could explain some of the
inconsistent results that have been reported previously in rodent (Snoek et al., 2010) and human
studies. Notably, the marginal effects observed after infusion of a constant dose of nicotine
through minipumps is consistent with lack of effects of nicotine using transdermal patches in
some UC studies (Pullan et al., 1994; Cosnes et al., 2004; McGilligan et al., 2007), suggesting
that a route of administration that mimics nicotine intake profile seen in smokers, could result in
an increase in the efficacy of treatment. Indeed, these and other (Eliakim et al., 1998; 2001;
2002; Sykes et al., 2000; Ghia et. al., 2006) results suggest that administering nicotine orally is a
very efficacious route in reversing colitis in rodent models. This outcome is consistent with that
obtained through UC studies using rectal administration of nicotine. A possible explanation for
these results is that nicotine targets and affects the colon locally when administered orally with
marginal therapeutic index. Other possible mechanisms of nicotine effects have been proposed.
For example, the beneficial effects of oral nicotine treatment could be due to nicotine exerting
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anti-inflammatory effects partially through changes in colonic TNF-α levels or through inhibition
of release of TNF-α and other pro-inflammatory cytokines from cytokine-producing cells. In the
mouse colitis model used in this study, colonic TNF-α levels were reduced significantly by the
low dose of oral nicotine treatment, which is most likely mediated via suppression of proinflammatory cytokine release from macrophages and other cytokine-releasing immune cells as
part of the initial innate immune response to DSS.
Although the colon may be an important site of action for nicotine following oral
administration, the drug likely acts on many peripheral and central inflammatory pathways.
Indeed, nicotine is absorbed in the small intestine with low bioavailability (up to 45%) because
of a hepatic first pass effect (Benowitz et al., 1991; Compton et al., 1997; Zins et al., 1997). In
the present study, oral administration of nicotine in the drinking water yielded measurable levels
of nicotine in the plasma. For example, a plasma nicotine concentration of 18 ng/ml was found
after an oral administration of an active dose of 25 µg/ml of the drug.
It has been proposed that some nicotine metabolites contribute to the beneficial effect of
nicotine in UC patients, since the majority of nicotine is converted to cotinine (about 80%)
through the cotinine pathway and is present in smokers in blood at much higher concentrations
(about 250 to 300 ng/ml) than nicotine (Benowitz et al., 1983; Gori and Lynch, 1985; Benowitz
and Jacob, 1994). In the present study, this hypothesis was tested by administering cotinine
directly in the drinking water.

The results show that oral cotinine administration has no

protective effect in the mouse colitis model based on clinical parameters or measurement of
colon length. Plasma concentrations after 10 days of cotinine oral administration of 25 and 250
µg/ml were 90 and 1336 ng/ml, respectively. These plasma levels cover well and above the
concentration range of cotinine found after nicotine administration protocols used in our various
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studies. The lack of effect of cotinine suggests that this major metabolite does not mediate the
anti-inflammatory effects of nicotine reported in rodents and human studies. However, other
metabolites such as nornicotine, which is a component in tobacco as well as a minor systemic
metabolite of nicotine and is a nAChRs agonist (Papke et al. 2007), cannot be ruled out of the
effects of nicotine.
Overall, our results with nicotine suggest that the protective effects of the drug are influenced
by the route of administration and the dose of exposure. While nicotine is a non-selective
agonist at the various nAChRs subtypes, several in vitro and in vivo evidence suggest that α7
nAChRs subtypes mediate its anti-inflammatory effects. In addition, it has been reported that α7
nicotinic receptor subunit may play an important role in experimental colitis (Ghia et al., 2006;
2007) and its effect mediated through activation of the cholinergic anti-inflammatory pathway
(Wang et al., 2003; de Jonge et al., 2005; Kelso et al., 2006; Hamano et al., 2006). We therefore
investigated the role of α7 nAChRs in the development of experimental colitis in mice.
6.3. Influence α7 nicotinic receptors in mouse DSS colitis model
The results presented in our study show that mice lacking α7 nicotinic receptor develop a
marked increase in clinical colitis scores and colonic inflammation markers in the mouse DSS
model. In contrast, α7 nAChRs agonists and PAM reduced the severity of the disease at a narrow
range of doses. Taken together, these results strongly suggest an important role for a cholinergic
anti-inflammatory pathway in the development of colitis, which at least in part is mediated by α7
nAChRs.
In the present study, we showed that α7 KO mice treated with 2.5% DSS have a significant
increase in the disease activity index scores and decrease in the colon length; however, there were
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no body weight difference between the α7 deficient and WT mice treated with DSS. This was
accompanied by an increase in colonic histological damage and elevated pro-inflammatory
cytokine levels of TNF-α. TNF-α is an early pro-inflammatory mediator that plays an important
role in immuno-inflammatory responses and in the pathogenesis of UC (Yokota et al., 1988; and
Anand and Adya, 1999). These results are consistent with recent data from various animal models
of inflammation that point towards the α7 nAChR subtypes as an important player in cholinergic
modulation of inflammation (Wang et al., 2003; Wang et al 2004; Ulloa, 2005; de Jonge et al.,
2005; van Maanen et al., 2010). They are also in agreement with Ghia et al., (2009) study that
showed that α7-deficient mice treated with DSS for 5 days showed an exaggeration of the colitis
severity with an increase in the colonic inflammation including histological damage score, proinflammatory cytokine, IL-1β colonic levels and MPO activity compared with the WT mice. In
addition, nicotine pretreatment counteracted the colitis inflammation in WT and lacks its effect in
the α7 KO mice.
In line with our α7 KO observations, α7 nAChR agonists and PAM (PHA-543613, PNU120596 and choline) were effective in reversing the clinical parameters of colitis and shortening of
the colon induced by DSS in mice; however, PAM did not reverse the shortening of the colon
length. This reduction was less pronounced with histopathology damage scores and levels of
colonic TNF-α. The antinflammatory effects of all three α7 nAChR ligands occur at narrow dose
ranges with U-shape dose-response relationships, with choline being relatively the most effective
in that regard. Choline is an essential nutrient, a cell membrane constituent, a precursor in the
biosynthesis of acetylcholine, and a selective natural full α7 nAChR agonist (Papke et al., 1996
and Alkondon et al., 1997). Interestingly, choline level is low in the colonic tissues from UC
patients (Bjerrum et al., 2010). When choline administered orally, it is absorbed in the intestine
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(Lekim and Betzing, 1976; Pelech and Vance, 1984; Tian et al., 2012) and its uptake is localized
in the neural part of the intact intestine of the guinea pig small intestine (Snyder et al., 1973; Pert
and Snyder, 1974). Recently, the anti-inflammatory efficacy of choline in murine endotoxemia
and sepsis and its modulation of TNF release require α7 nAChR-mediated signaling (Parrish et al.,
2008). Possibly, the lack of choline protective effect could contribute, at least in part in the
development of colitis in active UC.
Our data with PNU-120596, a type II α7 nAChR PAM, suggest the presence of a pro“anticolitis” endogenous tone mediated by α7 nAChRs. Generally speaking, PAMs are compounds
that facilitate endogenous neurotransmission and/or enhance the efficacy and potency of agonists
without directly stimulating the agonist binding sites. PNU-120596 may be acting in the DSS test
through the enhancement of sub-threshold concentrations of endogenous α7 agonists, choline
and/or ACh (Sarter and Parikh, 2005; Parikh and Sarter, 2006). Supporting the possibility of
choline, PNU-120596 was recently reported to enhance the effects of sub-threshold, physiological
concentrations of choline on native α7 nAChR in hypothalamic neurons (Gusev and Uteshev,
2010).
Our results are at odds with the recent study of Snoek et al., (2010) who reported that while
AR-R17779 and GSK1345038A, two selective α7 nAChR agonists, reduced cytokine responses in
vitro, they worsened the effects of DSS-induced colitis at low doses. The highest doses of these α7
nAChR agonists ameliorated clinical parameters, without affecting colonic inflammation. Many
factors could account for the differences between the two studies. The route of administration
does not seems to play a major role since the protective effects in the DSS model in our study was
seen with α7 nAChR agonists after both systemic (via s.c. and i.p) and oral (via drinking water)
routes of administration. The efficacy at α7 nAChRs of the agonists used in the treatment is
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another possible factor. While no information on the pharmacological profile at nAChRs was
available for GSK1345038A, AR-R17779 is a potent and selective partial (approximately 70%
efficacy) α7 nAChR agonist (Papke et al., 2004). Both of our α7 nAChR agonists used are full α7
nAChR agonists. However, two major differences could have played an important role: the sex of
the mice used and the disease severity.
In our study, we used male mice to investigate the role of α7 nAChRs in experimental colitis,
while α7 nAChR agonists were tested in female mice in Snoek et al., (2010) report. This is an
important difference that could account for the lack of effects seen in the later study. Indeed, sex
differences to nicotine and nicotinic agonists in mice and rats were reported in pain (Craft and
Milholland, 1998; Damaj, 2001) and dependence measures and behaviors (Isiegas et al., 2009;
Lopez et al., 2003). Finally, Snoek et al., (2010) used a relatively low concentration of DSS (1.5%)
to induce experimental colitis in C57 female mice compared to 2.5% in male C57 mice used in our
study. The differences in severity of the disease may have affected susceptibility to DSS-induced
lesions and modified the efficacy of α7 nAChR agonists.
The narrow window of anti-inflammatory effects of α7 nAChR agonists and PAM as shown
by their U-shaped dose-effect curves in our results with the DSS test, was surprising. While drug
distribution and metabolism factors could account for such dose-response profile, the same
phenomenon was seen with three structurally different α7 nAChR agonists. This narrow window
could have been related to the desensitization properties of α7 nAChRs agonists reported in vitro.
However, a similar profile was observed with PNU-120596, a type II PAM known to cause a
dramatic slowing of receptor desensitization (Bertrand and Gopalakrishnan, 2007). Importantly,
this narrow U-shaped dose-effect curve was not seen with α7 nAChRs agonists and PAMs in
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animal models of cognition and pain (Rowley et al., 2010; Feuerbach et al., 2008; Timmermann et
al., 2007). Thus, making this phenomenon unique to the DSS experimental colitis in mice.
In conclusion, in the DSS colitis model, we found that α7 nAChR signaling may, at least in
part play an important role in the protection against colitis development in mice. α7 nAChR
agonists and PAM affected the clinical features of the DSS colitis disease and produced a Ushaped dose-response curve. Our results suggest that targeting α7 nAChRs is a viable therapeutic
approach for intestinal inflammation diseases such as ulcerative colitis treatment.
Even though it has been established that α7 nAChR is an essential component of the vagus
nerve activity in regulating cytokine production in the periphery (Tracey, 2007), nicotine can
have multiple nAChR-stimulated pathways. It has been reported that nicotine can mediate its
anti-inflammatory effect in immune cells such as macrophages through a non-α7 nicotinic
receptors manner (Matsunaga et al., 2001), for example, van der Zanden et al., (2009)
demonstrated that α4β2 nicotinic receptors mediate cholinergic anti-inflammatory effects in
intestinal macrophages. Recently, it has been reported that α4β2 receptors partially mediated the
nicotine anti-inflammatory effect through JAK2-STAT3 signaling pathway (Hosur and Loring,
2011).
6.4. Involvment of non-α7 nicotinic receptors in inflammation and experimental colitis
model
In our study, β2, and α5 nAChR subunits appear to not play a crucial role in the development
and expression of colitis severity since there were no differences seen in either of the clinical
parameters of disease activity score or the colon length in the β2, and α5 deficient mice and their
littermates WT DSS-treated mice. However, Orr-Urtreger et al., (2005) reported the involvement
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of α5, but not β4 nAChRs, in experimental colitis. In which, they reported that the percentage of
mice body weight loss and the disease activity score after DSS treatment were higher in α5 KO
but not β4 KO nAChRs mice.

The reason why α5 KO mice in their study displayed a

pronounced effect in increasing the disease severity, shortening of the colon length, colonic
MPO activity, and in histologyical damage score in DSS colitis model is unclear. The different
adapted scoring systems for disease severity and histopathological damage from different
experimental colitis models, may explain the varying observations. Here, we used similar DSS
concentration, but possibly their α5 null mice background generation differ from our α5 KO
mice. In addition, they did not report a mouse sex and strain they used in their study, since
mouse strains have different susceptibility to DSS-inducd colitis model (Mahler et al., 1998).
Moreover, their adapted disease activity index scoring system (Rachmilewitz et al., 2002)
included only two clinical parameters, body weight loss and rectal bleeding; however, our
combined score has four clinical features of colitis for disease activity index (Cooper et al.,
1993). In addition, their scoring system for the histology adapted from different model of colitis
(Karmeli et al., 2000); however, we evaluated the total histological damage degree (Iba Y et al.,
2003) for more details see Chapter 2, materials and methods section. Furthermore, in their study,
nicotine reduced disease activity score in α5 null mice, but not in WT, noteworthy, they used
similar dose and route of nicotine administration that we used and also has been reported to be
effective in several experimental colitis models (Eliakim et al., 1998, 2001; Qiu et al., 1997;
Ghia et al., 2006). Moreover, nicotine in their study did not reduce colonic MPO activity in the
WT mice; however, Qiu et al. (1997) reported that oral nicotine (5-20 ug/ml) reduced MPO
activity and colonic damage score. Similar observation reported by Ghia et al. (2006) after oral
nicotine administration (20 ug/ml).
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In our study, α9 and α10 nicotinic receptor subtype seems to play a role in colitis severity and
inflammation since chronic administration of α-RgIA, a α9α10 selective antagonist, at low dose
of 0.02 mg/kg attenuated the clinical parameters in DSS colitis mice. However, this dose did not
affect colonic inflammation including total histology damage score or colonic TNF-α levels. On
the other hand, at high dose (0.2 mg/kg), α-conotoxin RgIA had neither effect on the colitis
severity nor colonic TNF-α level. However, it significantly decreased the total colon histological
damage score in a dose-dependant fashion. α-conotoxin RgIA at all tested doses (0.02, 0.1, 0.2
mg/kg) was unable to reverse the shortening of the colon length of the DSS-treated mice. DSS
can cause colonic inflammation which may be due to the increase of the cholinergic cells number
at the site of inflammation. It has been reported that α9α10 nicotinic acetylcholine receptor
antagonists decreased the number of immune cells such as macrophages and lymphocytes, and
positive choline acetyltransferase cells at the site of nerve injury (Vincler et al., 2006). RgIA may
possibly act by a similar mechanism in the DSS-induced colitis model, that is, through
antagonism of α9α10 nicotinic acetylcholine receptors on immune cells to reduce the
inflammation development and disease activity. α-RgIA possibly mediate its anti-inflammatory
effect through immune system mechanisms; however, it not clear yet.
6.5. Summary
In summary, we demonstrated that seven days of DSS treatment induces acute colitis in
C57BL6 mice. Chronic oral administration of low doses of nicotine in the drinking water was
protective in DSS-induced colitis in mice as shown in the clinical parameters, inflammation
markers and histological features. However, modest effects were seen after intermittent s.c
injection or continuous infusion of nicotine. Collectively, these results highlight that dose and
route of administration play a critical role in the protective effect of nicotine in intestinal
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inflammation. Developing novel pharmaceutical formulation regimens such as topical nicotine
administration to the colon (enema) could lead to decreased adverse effects seen with systemic
nicotine use and ameliorate the clinical efficacy of nicotine in UC conditions. Also, the lack of
effect of cotinine suggests that this major metabolite does not mediate the anti-inflammatory
effects of nicotine reported in rodents and human studies.
In DSS colitis model, we found that the lack of α7 nAChR subtype is probably, at least in
part a source of colitis development in α7 deficient mice. Our findings supported by using
pharmacological evidence, where we found that selective α7 nAChR agonists PHA-543613 and
choline reduced clinical parameters in DSS-treated mice and inhibited the increase in the colonic
TNF-α levels.

A similar profile was observed with of PNU-120596, a positive allosteric

modulator for α7 nAChRs. Our results showed that these α7 nAChR agonists were protective in
the DSS model at a narrow dose range with a U-shaped dose-response curve.
For the non-α7 nAChRs; our results suggest that both β2 and α5 nAChR subunits do not
seem to play a role in colitis severity. Importantly, our data demonstrated for the first time that
α9 nAChR subtypes may play an important role in experimental colitis. The α9 nAChR selective
antagonist α-RgIA reduced the clinical parameters in the area under the curve of disease activity
scores. Similarly to -α7 nAChRs agonists, a U-shaped dose-response curve was observed with αRgIA treatment.
To our knowledge, we are the first to report the importance of the dose and route of nicotine
administration and the effect of cotinine, the α9α10 nicotinic acetylcholine receptor antagonist,
and the positive allosteric modulator for α7 nAChR in the DSS-induced colitis model in mice.
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6.6. Future Directions
This research opens up new avenues and strategy for experimental and clinical colitis research.
Our data clearly showed that α7 nAChRs agonists and PAMs are good therapeutic candidates for
treatment of colonic inflammation diseases such as UC. Indeed, the current UC conventional
therapy has poor efficacies and associated with undesirable adverse effects, or contraindicated in
some UC patients. However, further research is needed to understand the underlyning
mechanisms of the role of α7 nAChRs in colitis. For instance, nicotine has multiple targets,
actions, and mechanisms to produce its anti-inflammatory effects. Investigating the site of action
of the anti-inflammatory effects of nicotine, α7 nAChRs agonists and PAMs can clarify the
immune and non-immune targets of these drugs. For example, isolation of lamina propria and
spleen mononuclear cells by gradient centrifugation or whole blood from C57BL/6 mice or
peritoneal macrophages isolation from α7 WT/KO and measure some inflammatory mediators
could add new insight whether their anti-inflammatory effect mediated systemically or
perpherial in the immunce cells from colonic, or peritoneal cavity during DSS-induced colitis
period. Notably, nicotine treatment reversed colitis severity in vagotomized mice (Ghia et al.
2006, 2007). Although the vagus nerve innervates only the proximal two-thirds of the colon,
some studies the involvement vagus nerve in experimental colitis based on the cholinergic antiinflammatory pathway concept in rodents. In fact, recent study by Vida et al., (2011), reported
that systemic anti-inflammatory effect of the released acetylcholine of the celiac-mesenteric
ganglia from vagus nerve activation is mediated through the α7 nAChR of the splenic nerve. de
Jonge et al., (2005) demonstrated that macrophages inhibited after vagus nerve activation
through Jak2-STAT3 signaling pathway activation. Thus, the idea that α7 nAChR mediated
reduced inflammation through cholinergic vagus nerve activation and release of acetylcholine
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seems to be indirect and more complicated. The intracellular mechanisms that induce nicotinic
inhibition of macrophage activation involve the activation of anti-inflammatory Jak2/Stat3/Socs3
signaling pathways and inhibition of NF-κB signaling (Tracey, 2002; Gallowitsch-Puerta and
Tracey, 2005; de Jonge et al., 2005; Arredondo et al., 2006). The effects of nicotine on NF-κB
activity are significantly blocked by specific JAK2 inhibitor (AG-490) and STAT3 inhibitor
(NSC74859) (Hosur and Loring, 2011). It would be of a great interest to utilize these selective
inhibitors for JAK2 and/or STAT3 in vivo in DSS-treated mice and investigate the relevance of
these pathways in the effects of α7 nAChR selective agonists to clarify some of the intracellular
mechanisms.
The limited anatomical expression of α9α10 nAChRs might be an advantage in target these
nicotinic receptor which also, could decrease the possibility of undesirable effects to occur
especially the CNS side effects since the α9α10 subtype is neither express in brain nor in spinal
cord. Therefore, the availiabliliy of α9 KO mice and the new selective antagonist for these
receptors could help to understand the role of α9α10 subtype in inflammation and colitis.
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